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Introduction 
Patient Blood Management (PBM) is a holistic 
approach to the management of blood as a resource 
for each, single patient; it is a multimodal strategy that 
is implemented through the use of a set of techniques 
that can be applied in individual cases. Indeed, the 
overall outcome resulting from the implementation 
of PBM cannot be fully appreciated and explained 
simply by summing the effects of the single strategies 
and techniques used, since these can only produce the 
expected optimal outcome if used in combination1. 
PBM is, therefore, a patient-centred, multiprofessional, 
multidisciplinary and multimodal approach to the 
optimal management of anaemia and haemostasis (also 
during surgery), to limiting allogeneic transfusion 
needs in the peri-operative period, and to appropriate 
use of blood components and, when relevant, plasma-
derived medicinal products2. The concept of PBM is 
not centred on a specific pathology or procedure, nor 
on a specific discipline or sector of medicine, but is 
aimed at managing a resource, "the patient's blood", 
shifting attention from the blood component to the 
patient who, therefore, acquires a central and pre-
eminent role3,4. 
PBM combines the dual purposes of improving 
the outcomes of patients and reducing costs, being 
based on the patient rather than on allogeneic blood 
as the resource. For this reason, PBM goes beyond the 
concept of appropriate use of blood components and 
plasma-derived medicinal products, since its purpose 
is to avoid or significantly reduce their use, managing, 
in good time, all the modifiable risk factors that can 
lead to a transfusion being required5. These aims can 
be achieved through the so-called "three pillars of 
PBM" (Table I)5, which are crucial for making the 
paradigmatic shift that characterises the innovative, 
patient-centred approach: (i) optimising the patient's 
erythropoiesis; (ii) minimising bleeding; and (iii) 
optimising and exploiting an individual's physiological 
reserve to tolerate anaemia5. Each of these three key 
points is a strategic response to clinical circumstances 
that can cause adverse outcomes and necessitate the 
use of allogeneic transfusion therapy, namely anaemia, 
blood loss and hypoxia, respectively. 
PBM is, therefore, intended to guarantee all 
patients a series of personalised programmes, based 
on surgical requirements and the characteristics of 
the patients themselves, with the dual purposes of 
using allogeneic transfusion support appropriately and 
reducing the need for this resource. For this reason, PBM 
requires multidisciplinary and multimodal strategies to 
systematically identify, evaluate and manage anaemia 
(boosting, if necessary, individual physiological 
reserves) and to avoid or minimise blood losses.
It seems necessary to produce specific national 
standards. In fact, in the USA, PBM is the object 
of attention from the Association for Advancing 
Transfusions and Cellular Therapies (formerly known 
as the American Association of Blood Banks - AABB) 
which recently published the first edition of "Standards 
for a Patient Blood Management Program" precisely 
with the aim of supplying healthcare structures with 
solid elements for the standardisation of procedures and 
activities for implementing and/or optimising a PBM 
programme. The Society for the Advancement of Blood 
Management (SABM), also in the USA, has published a 
second edition of "Administrative and Clinical Standards 
for Patient Blood Management Programs"6 and the 
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Joint Commission has published seven parameters for 
measuring the performance of healthcare structures in 
the field of PBM7. 
Methodology for producing the recommendations 
for the implementation of a Patient Blood 
Management programme
The methodology used to prepare the recommendation 
grades is based on that described by the Grading of 
Recommendations Assessment, Development and 
Evaluation (GRADE) Working Group8. According to 
the GRADE system, recommendations are classified by 
grade, expressed in Arabic numbers (1, 2), according to 
their strength, and in letters (A, B, C), according to the 
quality and type of evidence derived from the studies.
In detail:
-  Grade 1: the authors are certain that the advantages 
for health clearly outweigh the disadvantages, 
in terms of both risk and financial cost. This is, 
therefore, a strong recommendation.
-  Grade 2: the authors are less certain, the balance 
between advantages and disadvantages is less clear. 
This is, therefore, a weak recommendation. 
As far as concerns the quality and type of evidence 
drawn from the studies on which the recommendations 
are based, these can be classified into three levels:
 -  Grade A: high level. The evidence is derived from 
numerous, consistent randomised trials without 
major limitations. It is unlikely that future research 
will change the conclusions of these trials. 
-  Grade B: moderate level. The evidence is derived from 
randomised clinical trials, but with major limitations 
(such as inconsistent results, wide confidence intervals, 
methodological weaknesses). Grade B is also attributed 
to recommendations deriving from strong evidence 
from observational studies or case series (for example, 
treatment effects or the demonstration of a dose-
response effect). Subsequent research could modify 
the conclusions of these trials. 
-  Grade C: low or very low level. The evidence is 
derived from the analysis of observational clinical 
studies with less consistent results, or from experts' 
opinions/clinical experience. Future research is likely 
to change the conclusions reached.
Table I - The three pillars of Patient Blood Management (modified from Hofmann A et al.5).
Period
Pillar 1 Pillar 2 Pillar 3
Optimisation of erythropoiesis Minimisation of blood loss Optimisation of tolerance of anaemia
Pre-operative
1. Detect anaemia.
2. Identify and treat underlying 
disorder(s) causing anaemia.
3. Re-assess the patient, if necessary.
4. Treat iron deficiency, sideropenic 
anaemia, anaemia of chronic disease 
and functional iron deficiency 
(the so-called "iron-restricted 
erythropoiesis").
5. Trea t  de f i c i enc ies  in  o the r 
haematinics.
1. Identify and manage bleeding risk.
2. Minimise iatrogenic bleeding.
3. Careful planning and preparation of 
the procedure.
4. Pre-deposit, in very selected cases.
1. Assess and optimise the patient's 
physiological reserve for tolerance 
of anaemia and risk factors.
2. Compare estimated blood loss with 
the individual patient's tolerable 
blood loss.
3. Formulate patient-specific blood 
management plan that includes 
the blood-conservation techniques 
appropriate for the individual case.
4. Adopt restrictive transfusion 
thresholds.
Intra-operative
6. Adequate planning of the operation 
after optimisation of erythropoiesis.
5. Meticulous haemostasis and surgical 
techniques.
6. Blood-sparing surgical techniques.
7. Blood-conserving anaesthetic 
techniques.
8. Autologous blood transfusion 
strategies.
9. Pharmacological strategies and 
haemostatic agents.
10. Point-of-care tests
5. Optimise cardiac output.
6. O p t i m i s e  v e n t i l a t i o n  a n d 
oxygenation.
7. Adopt restrictive transfusion 
thresholds.
Post-operative
7. S t imula te  ery thropoies is ,  i f 
necessary.
8. Be aware of drug interactions that 
can cause/worsen post-operative 
anaemia. 
11. Careful monitoring of the patient 
and management of post-operative 
bleeding.
12. Rapid warming/maintenance of 
normothermia (unless there is a 
specific indication for hypothermia).
13. Autologous blood transfusion, if 
appropriate.
14. Minimise iatrogenic bleeding.
15. Management of haemostasis and 
anticoagulation.
16. Prophylaxis of upper gastrointestinal 
tract bleeding.
17. Prophylaxis/treatment of infections.
8. Optimise tolerance of anaemia. 
9. Maximise oxygen delivery.
10. Minimise oxygen consumption.
11. Adopt restrictive transfusion 
thresholds.
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In brief: 
- Grade 1A: strong recommendation based on 
scientific evidence of high quality.
- Grade 1B: strong recommendation based on 
scientific evidence of moderate quality.
- Grade 1C: strong recommendation based on 
scientific evidence of low quality.
- Grade 2A: weak recommendation based on scientific 
evidence of high quality.
- Grade 2B: weak recommendation based on scientific 
evidence of moderate quality.
- Grade 2C: weak recommendation based on scientific 
evidence of low quality.
The clinical-organisational course of the patient 
undergoing elective major orthopaedic surgery
Pre-operative period and role of the pre-operative 
assessment
The pre-operative assessment is performed in 
order to obtain clinical and laboratory information 
supplementary to that acquired from the clinical history 
with the aim of9:
- confirming, or not, the planned diagnostic-therapeutic 
pathway (clinical management);
- identifying previously undetected disorders that 
must be treated before the operation or which make 
it necessary to modify the surgical or anaesthetic 
technique;
- limiting possible adverse outcomes or increasing the 
benefits for patient by modifying, if necessary, the 
clinical pathway;
- facilitating the evaluation of potential risks for the 
patient (including the possibility of informing the 
patient of a potentially increased risk);
- predicting possible post-operative complications;
- establishing the baseline reference parameters, 
which can be used for subsequent post-operative 
evaluations;
- considering the value of performing screening not 
related to the operation.
A pre-operative evaluation is always necessary when 
anaesthesia is planned. 
Selective use of pre-operative tests, based on the 
history, clinical examination, and type and invasiveness 
of the surgical and anaesthesiological procedures, helps 
the management of the patient.
In order to shorten the time spent in hospital and 
optimise the planning of elective surgery, the pre-
operative evaluation is performed in an out-patient 
setting (pre-admission), at an appropriate time before the 
operation (on average, 30 days before), and includes any 
additional clinical-diagnostic investigations needed10-12. 
In al l  candidates  for  elect ive surgery,  a 
multidisciplinary and multimodal approach must be 
used, based on an agreed programme of co-ordinated 
interventions, aimed at peri-operative management of the 
"patient's blood" as a resource. These interventions start 
with the pre-operative optimisation of erythropoiesis, 
haemostasis and tolerance of anaemia.
Depending on the organisation in different hospitals 
or healthcare authorities, pre-operative management 
of the resource "patient's blood" must guarantee a 
structured diagnostic-therapeutic pathway involving 
at least three specialists: a surgeon, an anaesthetist and 
a transfusion medicine specialist; these professionals 
collaborate in the setting of a multidisciplinary 
outpatient clinic (the Anaemia Clinic) which takes the 
role of case manager. The Anaemia Clinic must allow 
for, when necessary, the inclusion and collaboration 
of other medical staff, such as experts in haemostasis 
and thrombosis, haematologists, cardiologists or other 
specialists with expertise in identifying and treating, in 
a multidisciplinary and multimodal method, underlying 
disorders in candidates for elective surgery. Furthermore, 
the patient's general practitioner should be kept informed 
and, when possible, involved.
The pre-operative process starts in the surgical 
outpatient clinic (Figure 1). During this appointment 
the surgeon, having defined the indication for surgery, 
the grading of the intervention and its level of priority, 
takes the patient's history, with the purpose, among 
others, of detecting risk factors for bleeding. To this 
aim it can be useful to administer a questionnaire for 
an initial evaluation of bleeding disorders (Figure 212,13), 
which can be followed by appropriate pre-operative 
investigations.
Subsequently the patient is sent to the pre-operative 
administration office which, in conformity with locally 
used procedures, enters the patient into a specific 
pre-operative course aimed at booking and performing 
the pre-operative investigations and anaesthesiological 
evaluation, as well as adding the patient to the waiting 
list (surgical register).
Once the prescribed investigations have been 
performed in a centre for pre-operative examinations, 
the patient is sent to the pre-operative anaesthesiology 
clinic where the anaesthetist examines the results of 
the pre-operative investigations and evaluates the 
patient's clinical state; if the patient is considered fit 
for anaesthesia, the specialist defines the "risk class"14, 
obtains informed consent to the anaesthesia and 
prescribes the anaesthesiological pre-medication.
If the pre-operative investigations that have been 
carried out are not considered sufficient, the anaesthetist 
orders other investigations that will be performed, when 
possible, on the same day as ordered or, at any rate, as 
soon as possible (dedicated pre-operative pathway). 
Furthermore, the anaesthetist may consider that the 
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Figure 1 - Pre-operative flow-chart for patients undergoing elective major orthopaedic surgery and included in a Patient Blood 
Management programme.
patient is not fit for anaesthesia because of the presence 
of intercurrent or chronic disorders or anaemia, which 
require specific investigations and/or treatment. In this 
case, after consultation with the surgeon and/or other 
specialists of the Anaemia Clinic, the anaesthetist may 
decide to prescribe what is deemed useful, setting a new 
date for the anaesthesiological re-evaluation, through the 
centre for pre-operative investigations.
The specialists of the Anaemia Clinic (anaesthetist, 
surgeon, specialist in transfusion medicine, expert in 
haemostasis and thrombosis, haematologist, or other 
specialist with expertise in identifying and treating, in 
a multidisciplinary and multimodal method, underlying 
disorders in candidates for elective surgery), by 
adopting the strategies and techniques indicated in the 
three pillars of PBM (Table I)5, have the task of setting 
up the multidisciplinary programme of co-ordinated 
interventions, aimed at the peri-operative management 
of the resource "patient's blood". The three pillars of the 
PBM in the pre-operative period are:
1) Optimisation of erythropoiesis: detect anaemia; 
identify and treat its underlying causes; re-evaluate 
the patient, if necessary; treat iron deficiency and 
iron-deficiency anaemia, anaemia of chronic disease 
and functional iron deficiencies, so-called iron-
restricted erythropoiesis; treat deficiencies of other 
haematinics.
2) Minimise blood losses: identify and manage 
bleeding risk, minimise iatrogenic bleeding, plan 
the procedure carefully and prepare well; organise 
pre-operative autologous blood donation in very 
selected cases.
3) Optimisation of the tolerance of anaemia: assess 
and optimise the patient's physiological reserve 
to tolerate anaemia and risk factors; compare 
estimated blood loss with the individual patient's 
tolerable blood loss; formulate a personalised blood 
management programme that includes patient-
specific blood-conservation techniques; adopt 
restrictive blood transfusion thresholds.
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI
 Se
rvi
zi 
Srl
27
Blood Transfus 2016; 14: 23-65  DOI 10.2450/2015.0172-15
Patient Blood Managment
Information about strategies included in local 
PBM programmes should be supplied to all patients, 
preferably before their admission to hospital, because 
this improves compliance with diagnostic-therapeutic 
care pathways adopted in the healthcare structure.
- It is recommended that the patient's pre-operative 
evaluation, aimed at detecting any anaemia and 
optimising erythropoiesis, at identifying and managing 
bleeding risk as well as assessing and optimising the 
patient's personal physiological tolerance of anaemia 
and risk factors, be carried out at least 30 days 
before the planned date of the operation, in order to 
allow more detailed investigations and/or arrange 
appropriate treatment [1C]. 
- It is recommended that a structured questionnaire, 
aimed at picking up risk factors for bleeding, is 
included when taking the clinical history of an adult 
candidate for elective (orthopaedic) surgery [1C].
- It is recommended that all adult patients who 
are candidates for elective major orthopaedic 
surgery for which a multidisciplinary programme 
of co-ordinated interventions has been established 
involving the adoption of pharmacological and non-
pharmacological techniques aimed at optimising 
erythropoiesis, minimising blood losses and 
optimising tolerance of anaemia, before giving 
consent to one or more of the above-mentioned 
treatments, receive detailed information on their 
clinical state and strategies to limit allogeneic 
transfusion needs included in the local PBM 
programme; explanatory material prepared ad hoc 
by the hospital may be used for this purpose [1C]. 
Once the pre-operative process has been concluded 
with the patient deemed fit for anaesthesia, the patient 
undergoes the pre-admission surgical assessment, 
with the purposes of: a) re-evaluating the grading of 
the operation to be performed; b) re-assessing the 
patient's general and specific conditions; c) planning the 
procedure; d) filling in the clinical records and single 
treatment chart with the pre-operative prescriptions (for 
example: specific therapies to optimise erythropoiesis, 
antibiotic prophylaxis, anti-thrombotic prophylaxis); 
e) collecting the informed consent to the intervention.
Having reached this point of the diagnostic-
therapeutic care pathway, the patient is ready to be 
admitted to hospital on the planned day.
Figure 2 - Initial evaluation of bleeding disorders (modified from Liumbruno GM et al.12, Nichols WL et al.13).
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Intra-operative period
Once the patient has completed the pre-operative 
preparation for anaesthesia and the operation, on the 
planned day the patient is admitted to the surgical ward, 
where he or she is greeted by a nurse. The nursing staff fill 
in the nursing records with the planned assessment forms 
(for example: pain detection, detection of pressure ulcers) 
and check that the patient has been suitably prepared 
with respect to the pre-operative instructions provided.
Subsequently, the surgeon (and anaesthetist, if 
necessary), having checked the correct planning of the 
operation after optimisation of erythropoiesis and the 
use of other strategies and techniques indicated in the 
pre-operative period in the three pillars of the PBM 
(Table I)5, examines, and, if necessary, updates the 
clinical documentation, the single treatment chart and 
the informed consent to the procedure; the same surgeon 
marks the site of surgery.
Before entering the operating theatre, the nurse 
checks the anaesthesiological instructions, administers 
and records the treatments prescribed (general, 
antibiotic, pre-anaesthesia), takes any blood samples 
required and informs the patient about the surgical 
procedure; the nurse also checks that the patient is not 
wearing any jewellery or removable prostheses, checks 
the patient's personal hygiene (if necessary, inviting 
the patient to wash again before the operation), shaves 
the patient, when required, and cleans the area of skin 
involved by the operation with antiseptics. 
The patient is transported to the induction/recovery 
room, where the surgical team (anaesthetist and 
surgeon) re-evaluates him or her, "signs in" the patient 
(using the operating theatre check-list), informs the 
patient, if collaborative, about the procedures that will 
be performed and introduces one or more devices for 
intravenous access. The nurse monitors the patient's vital 
parameters and administers antibiotic prophylaxis; all 
the activities are recorded on the nursing form and on 
the single treatment chart
In the operating theatre the same team carries out the 
"time out" checks (operating theatre check-list), performs 
the operation and provides anaesthesia, optimises the 
macrocirculation, maintains homeostasis and takes 
samples for any intra-operative blood-chemistry tests. 
In this stage the three pillars of the PBM involve 
the following.
1) Optimisation of erythropoiesis: check appropriate 
timing of the surgery after optimisation of 
erythropoiesis.
2) Minimisation of blood loss: ensure meticulous 
haemostasis and use appropriate surgical techniques; 
adopt blood-sparing strategies; use blood-conserving 
anaesthetic techniques; use autologous blood 
transfusion, if foreseen by the personalised PBM plan 
drawn up by the case manager of the Anaemia Clinic; 
use pharmacological strategies and haemostatic 
agents; use point-of-care (POC) tests.
3) Optimisation of tolerance of anaemia: optimise 
cardiac output; optimise ventilation and oxygenation; 
adopt restrictive transfusion thresholds.
At the end of the intervention, the surgical team 
carries out the "sign out" controls (operating theatre 
check-list) and the patient is then transferred to the 
induction/recovery room for post-operative observation. 
Here the patient is re-assessed and monitored until his 
or her transfer to the ward; the same team prescribes 
the post-operative controls and treatments that must be 
carried out in the ward in the first 24 hours following 
the operation and which also have the purpose of 
correctly implementing the PBM strategies included 
in the multidisciplinary programme of co-ordinated 
interventions. 
Post-operative period
After the operation, the patient can be transferred 
to the surgical ward from which he or she came, or 
depending on needs and clinical conditions, can be 
admitted to an intensive or sub-intensive care facility.
The post-operative controls and treatments for the 24 
hours following the surgical intervention are prescribed 
by the anaesthetist and surgeon during the period that 
the patient regains consciousness.
During the post-operative period, besides the 
management of any urgent or emergency clinical 
situations, the co-ordinated interventions foreseen by the 
multidisciplinary programme, aimed at implementing 
the techniques and strategies included in the three pillars 
of PBM and reported here, must be carried out.
1) Optimisation of erythropoiesis: stimulate 
erythropoiesis, if necessary; consider drug 
interactions that can cause or enhance post-operative 
anaemia.
2) Minimisation of blood losses: ensure careful 
monitoring of the patient and management of 
post-operative bleeding; guarantee fast rewarming/
maintenance of normothermia (except when there 
is a specific indication for hypothermia); use 
autologous transfusion techniques if foreseen by the 
personalised PBM drawn up by the case manager of 
the Anaemia Clinic; minimise iatrogenic bleeding; 
manage haemostasis and anticoagulation; administer 
prophylaxis against upper gastrointestinal tract 
bleeding; give prophylaxis against infections and 
treat any that occur. 
3) Optimisation of the tolerance of anaemia: optimise 
the tolerance of anaemia; maximise oxygen delivery; 
minimise oxygen consumption; adopt restrictive 
transfusion thresholds.
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The above-mentioned strategies must be implemented 
throughout the post-operative period until the patient's 
clinical conditions have normalised, which is when the 
feasibility of the patient's discharge from hospital is 
evaluated. On discharge the ward doctor prepares the 
discharge letter and gives it to the patient. The discharge 
letter contains a description of the salient diagnostic-
therapeutic interventions performed, information on 
the domiciliary management of the surgical wound and 
any drains, as well as the pharmacological treatment 
(medication reconciliation).
Healing of the surgical wound and correct compliance 
with the prescribed domiciliary drug treatment must be 
checked at each outpatient follow-up until conclusion of 
the post-discharge process (30 days if the patient has not 
had a prosthesis implanted, 1 year if prosthetic material 
has been implanted).
The three pillars of Patient Blood Management
Optimisation of erythropoiesis
Pre-operative period
Detection of anaemia
The prevalence of pre-operative anaemia in surgical 
patients varies greatly, ranging from 5% (among 
geriatric patients with hip fracture) to 75.8% (among 
patients with stage D colon cancer according to Dukes' 
classification)15; among candidates for orthopaedic 
surgery associated with moderate to substantial peri-
operative bleeding, such as elective joint replacement 
(of the hip or knee) or urgent surgery (of the hip), 
the prevalence of pre-operative anaemia ranges from 
24±9% to 44±9%, respectively16. Epidemiological 
studies on anaemia in patients undergoing elective hip 
or knee replacement surgery showed that the anaemia 
is hypochromic and microcytic in between 23 and 70% 
of cases16. Figure 3 presents a simple algorithm for the 
diagnosis of iron-deficiency anaemia17-19. Among the 
same patients the prevalence of vitamin B12 deficiency 
is about 12% and that of folate deficiency about 3%20,21. 
The other forms of anaemia are due to inflammatory 
disease, chronic kidney disease or an unknown cause22,23. 
Pre-operative anaemia, even if mild, in patients 
who are candidates for major surgery (not cardiac) is 
independently associated with a higher risk of morbidity 
and mortality at 30 days24. Furthermore, a recent, 
retrospective study demonstrated that, in the peri-
operative period of patients undergoing heart surgery, 
the sum of two risk factors, that is anaemia (haematocrit 
<25%) and transfusion therapy with red cell concentrates, 
had a greater, and statistically significant, effect on post-
operative morbidity and mortality25. Anaemia is, therefore, 
a contraindication to performing elective surgery. 
It is recommended that elective major surgery is not 
performed in patients who are found to have anaemia 
until the anaemia has been correctly classified and 
treated [1B]. 
Anaemia is defined according to threshold values 
of haemoglobin (Hb) indicated by the World Health 
Organization (WHO)26: children up 5 years: 110 g/L; 
children between 5 and 12 years old: 115 g/L; children 
between 12 and 15 years: 120 g/L; pregnant women: 110 g/L; 
women who are not pregnant (aged 15 years old or 
more): 120 g/L; men (aged 15 years or more): 130 g/L.
It is recommended that the pre-operative assessment 
of the patient, aimed at detecting any anaemia and 
optimising erythropoiesis, is performed at least 30 days 
before the planned date of the operation, in order to 
enable more detailed diagnostic investigations and/or 
plan appropriate treatment [1C]6,11,12. 
It is recommended that, if a state of anaemia is 
detected, the subsequent laboratory tests are directed at 
identifying iron deficiency or other nutritional deficiencies 
(folic acid and/or vitamin B12), chronic kidney disease 
and/or chronic inflammatory disorders [1C].
It is recommended that the detection and treatment 
of anaemia, and any further related clinical-diagnostic 
investigations, are included within a global PBM 
strategy become a standard of care for all candidates for 
elective surgery, especially if the risk of peri-operative 
bleeding is substantial [1C].
Stimulation of erythropoiesis
These recommendations concern the management 
of oral and intravenous iron therapy, given the paucity 
of studies on the use of other haematinics in the peri-
operative setting27. 
Since the pre-operative Hb value is the main, 
independent risk factor for requiring transfusion support 
with packed red cells, it is recommended that any 
nutritional deficiencies (iron, vitamin B12, folate), once 
detected, are treated with haematinics [1C]11. 
It is suggested that the target Hb value before 
elective major orthopaedic surgery is at least within the 
normal range according to the previously cited WHO 
criteria [2C]11.
Oral iron therapy
In adult patients with iron-deficiency anaemia who 
are candidates for elective hip or knee replacement 
surgery, oral iron therapy, particularly if combined with 
restrictive transfusion protocols, has been found to be 
effective in the treatment of pre-operative anaemia, 
in limiting transfusion needs and, in some cases, also 
reducing the duration of time spent in hospital28-30. 
It is suggested that oral iron therapy is used for 
the treatment of pre-operative iron-deficiency and to 
minimise transfusion requirements in adult patients who 
are candidates for elective major orthopaedic surgery [2B].
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Intravenous iron therapy
The pre-operative use of intravenous iron to treat 
adult patients with iron-deficiency anaemia who are 
candidates for major surgery, including orthopaedic 
surgery, has been shown to be effective in correcting 
anaemia and limiting transfusion requirements31-33. 
A recent randomised, multicentre study demonstrated 
the superiority (and safety) of infusion of iron 
carboxymaltose with respect to iron therapy per os in 
the correction of iron-deficiency anaemia in patients 
with a poor response to oral therapy34. 
It is suggested that intravenous iron therapy is 
used for the treatment of pre-operative iron-deficiency 
anaemia and to limit transfusion requirements in 
adult patients who are candidates for elective major 
orthopaedic surgery [2A].
Post-operative period
Detection of anaemia
Anaemia develops in 74% of patients during 
hospitalisation (including those admitted with normal 
Hb values) and, besides causing a substantial use 
of resources, in part because of the prolongation 
of the time spent in hospital, is associated with 
significant increases in mortality35 and morbidity11. The 
prevalence of anaemia in the post-operative period in 
patients who have undergone elective or urgent major 
orthopaedic surgery is much higher, being 51% and 
87%, respectively16. Furthermore, anaemia, which can 
be present in as many as 90% of surgical patients15, 
although caused mainly by peri-operative bleeding, 
can be worsened by repeated withdrawal of blood for 
laboratory tests and by ineffective erythropoiesis due 
Hb<120 g/L (females) – Hb<130 g/L (males) 
Transferrin saturation <20% 
Ferritin <30 μg/L + 
MCH* <27 pg Ferritin: 30-100 μg/L Ferritin >100 μg/L 
Iron-deficiency anaemia 
(gastro-enterological, 
gynaecological 
evaluation, etc.) 
Anaemia of chronic 
disease + iron 
deficiency** 
Anaemia of chronic 
disease*** 
Oral or intravenous 
iron therapy 
Treatment with 
erythropoietin 
Hb<120-130 g/L 
Figure 3 - Algorithm for the diagnosis of iron-deficiency anaemia (modified from Muñoz 
M et al.17-19).
 Hb: haemoglobin; MCH: mean corpuscular haemoglobin; The dashed arrow indicates the 
need to measure the ferritin level; *: The mean corpuscular volume (MCV) is a relatively 
late indicator of iron deficiency in patients without active bleeding; in the presence of a low 
MCV the differential diagnosis from thalassaemia must be made; the MCV can be normal in 
the presence of vitamin B12 or folate deficiency, post-haemorrhagic reticulocytosis, initial 
response to oral iron therapy, alcohol intake or myelodysplasia. ** Additional laboratory 
tests: reticulocyte count; creatinine; C-reactive protein. *** Additional laboratory tests to 
evaluate the iron deficiency: ratio between soluble transferrin receptor (sTfR) and logarithm 
of ferritin; hypochromic red blood cells; haemoglobin content in reticulocytes.
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to the inflammatory response induced by the surgical 
procedure itself36,37. This inflammation reduces the 
availability of iron for erythropoiesis through inhibition 
of its intestinal absorption and a reduction in hepcidin-
mediated mobilisation of iron stores23,38-40. 
The best strategy to prevent post-operative anaemia 
and avoid transfusions is to detect and correct any 
anaemia present in the pre-operative period, when 
possible11. 
However, most adults in good health with normal 
baseline levels of Hb do not normally require transfusion 
therapy with packed red cells following a surgical 
intervention provided that the loss of blood during the 
intervention is less than 1,000 mL and the intravascular 
volume is maintained with crystalloids or colloids12,41. 
Stimulation of erythropoiesis
Oral iron therapy
As already mentioned, the ineffective erythropoiesis 
caused by the post-operative inflammatory response36,37, 
which inhibits intestinal absorption of iron and reduces 
the mobilisation of iron stores, makes oral iron therapy 
unfeasible in the post-operative period23,38-40. 
Indeed, various randomised studies have demonstrated 
that oral iron therapy in patients undergoing elective or 
urgent orthopaedic surgery is not only not effective at 
correcting the post-operative anaemia and reducing 
transfusion requirements, but is also often associated 
with the development of adverse events42-44. 
Oral iron therapy is not recommended for the 
treatment of post-operative anaemia and minimisation 
of transfusion needs in patients undergoing elective or 
urgent major orthopaedic surgery [1B].
Intravenous iron therapy
Intravenous administration of iron in the post-operative 
period, in patients who have undergone lower limb 
arthroplasty45,46 or correction of scoliosis47, is effective at 
correcting anaemia and limiting transfusion needs.
It is suggested that intravenous iron therapy is used 
for the treatment of post-operative anaemia and to limit 
transfusion needs in patients undergoing elective major 
orthopaedic surgery [2C]. 
Short-term management in the peri-operative period
Stimulation of erythropoiesis
Iron therapy
In orthopaedic patients with hip fractures, the 
short-term use of intravenous iron and adoption of 
restrictive transfusion strategies were demonstrated 
to be effective in limiting transfusion requirements, 
particularly in non-anaemic patients48-50; other studies, 
in anaemic patients, showed that intravenous iron was 
more effective if combined with recombinant human 
erythropoietin51,52. 
Similar results were obtained in patients undergoing 
knee replacement surgery53. Recently a large, 
observational study in patients who underwent elective 
lower limb arthroplasty or urgent surgery for hip fracture 
further confirmed the above described results: short-
term infusions of iron were found to be effective with 
or without concomitant treatment with erythropoietin54. 
Short-term treatment with intravenous iron is 
suggested in order to minimise transfusion requirements 
in adult patients undergoing elective major orthopaedic 
surgery who are at risk of severe anaemia in the post-
operative period [2B].
Dose of iron therapy
Oral iron
A recently published randomised clinical trial in 
critically ill patients with iron-deficiency anaemia 
demonstrated that 65 mg of elemental iron/die per os are 
effective at reducing transfusion requirements.
A dose of 100 mg of elemental iron/die for 2-6 weeks 
prior to the surgical intervention is recommended for 
the treatment of pre-operative anaemia [1C]55. 
Intravenous iron
It is suggested that the dose of intravenous iron 
needed to replenish iron stores is calculated using 
Ganzoni's formula19,56: "total iron requirements (mg) = 
[desired Hb ‒ actual Hb (mg/dL)] × weight (kg) × 0.24 
+ 500 mg (for iron stores)" [2C].
The therapeutic regimen to adopt varies depending 
on the formulation of iron used. 
It is suggested administering 200 mg of elemental 
iron intravenously for every 500 mL of blood lost [2C]27. 
Safety of intravenous iron therapy
Numerous studies performed in thousands of patients 
in different clinical settings have demonstrated the 
safety of intravenous iron therapy57,58. The European 
Medicines Agency (EMA) recently published "New 
recommendations to manage risk of allergic reactions 
with intravenous iron-containing medicines"59. A year 
later, in 2014, Rampton et al. published guidelines 
for the management of hypersensitivity reactions to 
intravenous iron60.
According to the Committee for Medicinal Products 
for Human Use (CHMP) of the EMA: a) intravenous 
iron-based medicines should be used when oral 
iron cannot be used or does not work, particularly 
in patients in dialysis, in the peri-operative period, 
or in the presence of disorders of gastrointestinal 
absorption; b) the benefits of intravenous iron outweigh 
its risks, provided that appropriate measures are taken 
to minimise the possibility of allergic reactions; c) the 
data on the risk of hypersensitivity come mainly from 
spontaneous post-marketing notifications and the total 
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number of deaths or life-threatening events is low; d) 
these data cannot be used to pick up any differences 
in the safety profile of the various iron-containing 
preparations.
The CHMP of the EMA has also produced the 
following recommendations for healthcare staff, with 
the aim of improving patients' safety.
A) Intravenous iron must only be administered when 
"staff trained to evaluate and manage anaphylactic 
and anaphylactoid reactions" and "resuscitation 
facilities" are immediately available. 
B) A test dose is no longer recommended. 
C) If a hypersensitivity reaction occurs, "healthcare 
professionals should immediately stop the iron 
administration and consider appropriate treatment 
for the hypersensitivity reaction". 
D) "Patients should be closely observed for signs and 
symptoms of hypersensitivity reactions during and 
for at least 30 minutes following each injection of 
an intravenous iron medicine." 
E) Intravenous iron is contraindicated in patients with 
hypersensitivity to the active substance or excipients 
or to other iron-containing products administered 
parenterally. 
F) The risk of hypersensitivity is increased "in patients 
with known allergies or immune or inflammatory 
conditions and in patients with a history of severe 
asthma, eczema or other atopic allergy." 
G) "Intravenous iron products should not be used during 
pregnancy unless clearly necessary" and their use 
"should be confined to the second or third trimester, 
provided the benefits of treatment clearly outweigh 
the potential serious risks to the foetus such as anoxia 
and foetal distress."
As far as concerns the safety of intravenous iron, 
Auerbach and Macdougall state that, based on all 
retrospective and prospective studies, provided that 
high molecular weight iron dextran is avoided, which 
is no longer on the market, all the other preparations 
are safe and probably much safer than most doctors 
perceive58,61. 
In contrast, as far as concerns the risk of infections 
the data currently available in the literature do not allow 
definitive conclusions to be drawn and, for this reason, 
it is suggested that intravenous iron therapy is avoided 
in patients with acute infections [2C]27,57. 
It is suggested that intravenous iron is not 
administered to patients with ferritin values >300-500 
ng/mL and with a transferrin saturation >50% [2C]27. 
Use of erythropoietin in the peri-operative period
There are two possible strategies for the use of 
erythropoietin in the peri-operative period12: the 
erythropoietin can be administered to optimise 
autologous donation, in the very few cases in which 
autologous donation is indicated, or it can be used in 
patients who are candidates for elective surgery who 
cannot complete a predeposit programme, in the very 
few cases in which such a programme is indicated. 
However, the prescription of erythropoietin α, β 
and z is currently paid for by the National Health 
Service if used as a treatment to increase the amount 
of autologous blood in the setting of a pre-operative 
deposit programme, with the limitations set out in 
the technical data sheet. Erythropoietin α can also 
be charged to the National Health Service when 
prescribed to reduce allogeneic transfusions in 
adults patients who are candidates for elective major 
orthopaedic surgery considered to involve a high risk 
of complications requiring transfusion, for which a 
pre-operative autologous blood donation programme 
is not available.
Erythropoietin has been found to be effective in 
limiting transfusion requirements in candidates for lower 
limb elective joint replacement surgery62-64, although the 
costs are unacceptable65. 
It is suggested that erythropoietin is administered to 
adult candidates for elective major orthopaedic surgery 
who undergo a pre-deposit programme in which the 
donation of at least three units of whole blood is planned 
or for which a pre-deposit programme is not available 
and it is expected that the blood loss will be greater than 
1,000 mL [2B].
In order to avoid a "functional deficiency" of iron 
during treatment with erythropoietin, it is suggested that 
intravenous iron is administered [2B]12,66-69. 
Minimisation of blood loss
Pre-operative period
Pre-deposit
Pre-deposit autologous blood transfusion consists in 
collecting units of blood from the patient (pre-deposit), 
storing them (without fractionation) and using them 
exclusively for the patient-donor. It has been widely 
shown that pre-depositing blood increases the risk of 
requiring transfusion therapy, including allogeneic 
transfusions70. 
In adult candidates for elective major orthopaedic 
surgery, it is recommended that the practice of pre-
deposit is limited to subjects with rare red blood cell 
groups or complex alloimmunisation, for whom it is 
impossible to find compatible blood components [1A]12,69. 
In any case, there is no need for autologous blood 
collection if the patient's basal Hb is such that, considering 
peri-operative losses, a stable, post-operative Hb of 100 
g/L or more can be expected. 
Contraindications to the collection of autologous 
blood are:
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- Hb values lower than the threshold values indicated 
by the WHO to define anaemia [children up 5 years: 
110 g/L; children between 5 and 12 years old: 115 
g/L; children between 12 and 15 years: 120 g/L; 
pregnant women: 110 g/L; women who are not 
pregnant (aged 15 years old or more): 120 g/L; men 
(aged 15 years or more): 130 g/L]26; 
- severe heart disease;
- positivity for one of the following tests, the results of 
which must be known before starting the autologous 
pre-deposit programme: HBsAg, anti-HCV antibodies, 
anti-HIV 1-2 antibodies;
- epilepsy; 
- ongoing bacteraemia.
However, even in the presence of criteria for 
exclusion from autologous blood collection, a patient 
can, exceptionally, be accepted if the indications are 
appropriate and there are specific, documented clinical 
circumstances motivating the recourse to autologous 
donation. 
It is recommended that the interval between 
collecting one unit of autologous blood and the next is at 
least 7 days and that, in all cases, the last unit is collected 
at least 7 days before the planned operation [1C]71-76. 
Identifying and managing the risk of bleeding
The second pillar of PBM includes all the strategies 
to minimise bleeding and preserve the individual blood 
reserves.
These strategies are applied right from the pre-
operative stage, through the definition of parameters 
to stratify bleeding risk, that is, a detailed history and 
thorough clinical examination. Much care must be given 
to the patient's drug history, since the number of patients 
being treated with antiplatelet agents, anticoagulants, 
anti-inflammatory drugs and antidepressants or 
herbal products with antiplatelet effects is increasing 
continuously.
Recent guidelines (British, Australian and Italian)12,77-79 
recommend the use of structured questionnaires to 
reduce bleeding and preserve individual blood reserves 
through the identification of patients at risk of bleeding 
and for a potential quantification of the bleeding risk in 
patients with congenital clotting disorders80. 
In fact, in the context of pre-operative screening, a 
standardised questionnaire covering the patient's clinical 
and drug history seems to be superior to an assessment 
based only on the results of common laboratory 
tests [activated partial thromboplastin time (aPTT), 
prothrombin time /International Normalized Ratio (PT/
INR), platelet count]81.
The second important element is the physical 
examination of the patient, which is aimed at detecting 
any signs of cutaneous bleeding (petechiae, ecchymoses, 
haematomas) which could suggest the presence of 
liver disease, a congenital clotting disorder or platelet 
disorder82. 
Although various guidelines recommend the use 
of standard laboratory tests (aPTT, PT, platelet count) 
in the pre-operative period to define the bleeding 
risk77,79,83, a systematic review demonstrated that altered 
coagulation screening tests in the pre-operative period 
are not predictive of intra- or post-operative bleeding84. 
However, given their low cost and for reasons of 
prudence, the guidelines of the Italian Society for the 
Study of Haemostasis and Thrombosis (SISET) suggest 
that these tests are performed79. 
Low plasma levels of fibrinogen seem to be predictive 
of an increased risk of intra-operative bleeding in heart 
surgery85. 
Results of clotting tests performed in the pre-operative 
period with point-of-care (POC) instruments do not 
predict bleeding during or after surgery86,87, whereas 
monitoring haemostasis by POC instruments during the 
intra-operative phase is useful for assessing the causes 
of bleeding.
Although there are reports on possible correlations 
be tween some haemostas is - re la ted  genet ic 
polymorphisms or mutations and an increased risk of 
surgical bleeding, at present it is not possible to assign 
a clear predictive value to genetic tests88.
Platelet function can be assessed through the use of 
several analysers (PFA 100/200, CPA Impact-R, MEA 
Multiplate, PlateletWorks, VerifyNow), which have a 
varied sensitivity for the different antiplatelet drugs. 
However, given the variability and poor standardisation 
of tests to determine platelet function, the SISET 
guidelines do not recommend their routine use prior 
to surgery79. However, the guidelines of the European 
Society of Anaesthesiology suggest evaluating platelet 
function in the case of a positive history of bleeding 
and in the case of known alterations in platelet function 
because of congenital disorders or medication use88.
Correct pre-operative management of the bleeding 
risk in surgical patients involves appropriate interventions 
to acquired factors (drugs, diseases) or congenital 
conditions predisposing to bleeding.
It is recommended that a careful personal and family 
history is taken from the patient in order to pick up any 
bleeding risk, information about ongoing medication 
use or the consumption of any over-the-counter or 
herbal products, because this assessment is considered 
more informative of peri-operative bleeding risk than 
isolated evaluation of results of pre-operative screening 
coagulation tests [1C].
It is suggested that the platelet count, PT and aPTT 
are determined before every surgical intervention or 
invasive procedure that carries a risk of bleeding [2C].
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In the case of a positive history of bleeding, it is 
suggested that an expert in haemostasis is consulted in 
order to diagnose possible bleeding syndromes [2C].
Minimising iatrogenic blood loss and planning the procedure
Management of antiplatelet treatment
It is known that cyclo-oxygenase-2-selective non-
steroidal anti-inflammatory drugs are not responsible 
for increased bleeding during total knee or hip 
replacement89-91 and, for this reason, it is not necessary 
that the use of these drugs is suspended before elective 
lower limb arthroplasty. In contrast, ibuprofen, 
diclofenac and indomethacin significantly increase 
blood loss during total knee replacement surgery92, and 
so the use of these drugs should be suspended.
Monotherapy with aspirin (ASA) or clopidogrel 
does not need to be stopped before urgent orthopaedic 
surgery nor is it necessary to delay surgery in patients 
taking these drugs93,94. 
According to a recent Italian intersociety consensus 
statement95 ASA, if taken for primary prevention, should 
be suspended 7 days before elective arthroplasties 
whereas it should be stopped on admission to hospital in 
the case of fracture of the femoral neck. If it is being taken 
for secondary prevention (i.e., in a patient who has had 
a previous cardiovascular event), it should be continued 
in the peri-operative period at a dose of 75-100 mg/die. 
It is suggested that cyclo-oxygenase-2-selective 
non-steroidal anti-inflammatory drugs are not suspended 
prior to elective lower limb joint replacement surgery 
[2B].
It is suggested that ibuprofen, diclofenac and 
indomethacin are suspended prior to elective lower limb 
joint replacement surgery [2B].
It is recommended that ASA monotherapy, being 
taken for secondary prevention, is not suspended before 
elective lower limb joint replacement surgery [1B].
Ticlopidine and clopidogrel belong to the family 
of thienopyridines, being first- and second-generation 
examples, respectively; both inhibit ADP-induced 
platelet activation by binding to the P2Y12 receptor. 
Prasugrel is a third-generation thienopyridine, which 
must be converted to its active metabolite before binding 
to the P2Y12 platelet receptor. Thienopyridines have 
much stronger antiplatelet activity than ASA.
Various studies have described peri-operative 
bleeding complications in association with the use of 
clopidogrel and the risk of bleeding can increase when 
clopidogrel is given together with ASA. At present, there 
are no data available on the use of prasugrel in the peri-
operative period; the platelet inhibition induced by this 
drug lasts at least 7 days88. 
Ticagrelor, another antiplatelet agent, unlike the 
thienopyridines, has a direct effect on the P2Y12 
receptor, without requiring biotransformation by the P450 
cytochrome; it has a rapid onset of action and the platelet 
inhibition decreases to 10% after about 4.5 days96. 
Since clopidogrel and prasugrel are responsible for 
peri-operative bleeding, it is recommended that these 
drugs are suspended 5 and 7 days, respectively, before 
surgery, in cases of increased bleeding risk [1C]. 
It is suggested that ticagrelor is suspended 5 days 
pre-operatively [2C].
Patients with acute coronary syndrome or those 
undergoing angioplasty benefit from dual antiplatelet 
therapy with a combination of ASA and another platelet 
anti-aggregant drug (thienopyridine or ticagrelor), even 
if this increases the risk of bleeding complications97. 
In the case of urgent or emergency surgery, it 
is recommended that the decision regarding the 
continuation of treatment with antiplatelet drugs in the 
peri-operative period is the result of a multidisciplinary 
evaluation [1C].
It is suggested that urgent or emergency surgical 
interventions are performed, maintaining dual 
antiplatelet therapy (ASA/clopidogrel; ASA/prasugrel; 
ASA/ticagrelor) or at least ASA, when the bleeding risk 
is high [2C].
Oral dual antiplatelet therapy is necessary for patients 
with stents, in whom the suspension of one or both of the 
anti-aggregant drugs, particularly in the first months after 
the procedure, carries a significant risk of thrombosis 
of the stent, which is a potentially fatal event98. The 
growing number of coronary artery revascularisation 
procedures carried out each year is inevitably leading 
to an increase in the number of patients with coronary 
artery stents who must undergo surgical interventions. 
The management of antiplatelet therapy in these patients 
is often arbitrary, despite it being a critical factor in the 
prevention of ischaemic-haemorrhagic complications.
It is recommended that elective orthopaedic 
surgery is not performed during the first 3 months 
after implantation of a metal stent or during the first 12 
months after implantation of a drug-eluting stent [1C].
Management of anticoagulant therapy 
Vitamin K antagonists (VKA) are used for the 
prophylaxis or treatment of thromboembolic events, 
particularly in patients with mechanical heart valves, atrial 
fibrillation or a past history of venous thromboembolism. 
It is not always necessary to suspend the use of these 
drugs and the decision depends on the type and site of 
the operation or invasive procedure88,99,100. 
In  pa t ien t s  wi th  a  low/medium r i sk  o f 
thromboembolism, it is suggested that VKA treatment 
is suspended 5 days before the planned elective joint 
replacement surgery and bridging therapy is established 
[administering low molecular weight heparin (LMWH) 
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at prophylactic doses] in the following way: last dose 
of VKA on day –5; first subcutaneous dose of LMWH 
once a day, starting on day –4 if the patient was being 
treated with acenocoumarol, and starting on day – 3 if 
the patient was being treated with warfarin [2C].
In patients at high risk of thromboembolism [i.e., 
with atrial fibrillation and a CHADS2 (Congestive 
heart failure, Hypertension, Age ≥75 years, Diabetes 
mellitus, prior Stroke or transient ischaemic attack or 
thromboembolism) score >2; with recurrent venous 
thromboembolism treated for less than 3 months; 
with a mechanical heart valve] it is recommended 
that bridging therapy (LMWH at therapeutic doses) is 
given in the following manner: last dose of the VKA on 
day –5; first subcutaneous dose of LMWH twice daily 
starting from day –4 if the patient was being treated with 
acenocoumarol, and starting from day –3 if the patient 
was being treated with warfarin [1C]. 
An Italian study demonstrated the efficacy and safety of 
using reduced therapeutic doses (65-70 IU/kg twice daily) 
instead of the classical bridging therapy with 100 IU/kg 
twice daily100.
It is suggested that the last dose of LMWH is 
administered 12 hours before a planned operation 
and/or invasive procedure, except when a full dose of 
anticoagulant is being used, in which case an interval 
of 24 hours is suggested [2C].
The new oral anticoagulants
Dabigatran etexilate is an oral inhibitor of thrombin. 
It has a half-life of 14-17 hours, is eliminated mostly 
(80%) in the urine, does not interact with food and does 
not necessitate blood tests for monitoring. It is indicated 
for the prevention of venous thromboembolism in major 
orthopaedic surgery, for the prevention of emboli in 
patients with atrial fibrillation and in the treatment 
and secondary prevention of deep vein thrombosis and 
pulmonary embolism101-105. 
Rivaroxaban and apixaban are oral inhibitors of 
activated factor X (FXa). They have half-lives of 9-12 
hours and 10-15 hours, respectively; rivaroxaban is 
eliminated mainly through the kidneys (although only 
half in an active form), while apixaban is eliminated 
partly through the hepatic route and partly in the 
urine. Both are indicated for the prevention of venous 
thromboembolism in major orthopaedic surgery, for the 
prevention of emboli in patients with atrial fibrillation 
and for secondary prevention of deep vein thrombosis 
and pulmonary embolism106-113. 
The management of new oral anticoagulant (NOAC) 
use during surgical interventions is based largely on the 
consensus of opinions of experts, although the experts 
have produced contrasting advice, particularly with 
regards to the indication for and duration of bridging 
therapy with parenteral anticoagulants, which is 
proposed by some experts also for patients being treated 
with NOAC. Indeed, this is the strategy suggested 
by the recent guidelines from the European Society 
of Anaesthesiology88. Some scientific societies have 
suggested indications for suspending or not suspending 
treatment with NOAC114. Based on the pharmacokinetic 
and pharmacodynamics characteristics of NOAC, a 
temporary (short-term) suspension of these drugs is 
possible without requiring bridging therapy, which 
would expose the patient to a higher risk of bleeding, as 
demonstrated by recent registry data115. For this reason 
the following recommendations and suggestions reflect 
the literature data and recent guidelines of the European 
Heart Rhythm Association (EHRA), which do not 
include the use of bridging therapy114,116-118.
Table II shows the stratification of bleeding risk 
in relationship to invasive procedures or surgical 
interventions: the bleeding risk is defined as "clinically 
unimportant", "low" or "high"114. 
It is suggested that NOAC (dabigatran, rivaroxaban, 
apixaban) are not suspended and that the operation 
is performed 12-24 hours (depending on whether the 
drug is admin stered, respectively, once or twice a 
day) after the last dose in the case of: dermatological 
surgery, dental procedures, gastroscopy and colonoscopy 
(without biopsies), ocular interventions (particularly 
of the anterior chamber, such as cataract surgery) and 
operations involving a clinically unimportant risk of 
bleeding (see Table II) [2C]114.
It is suggested that NOAC are suspended 24 hours 
before elective surgery that carries a low risk of bleeding, 
in patients with normal renal function [creatinine 
clearance (CrCl) ≥80 mL/minute] [2C].
It is suggested that NOAC are suspended 48 hours 
before elective surgery that carries a high risk of 
bleeding in patients with normal renal function (CrCl 
≥80 mL/minute) [2C].
In patients with impaired renal function, the suspension 
of the NOAC should be graduated according to the type 
of drug and the CrCl, as indicated in Table III114. 
It is suggested that rivaroxaban and apixaban are 
suspended 36 or 48 hours before surgery with a low or high 
bleeding risk, respectively, in patients with a CrCl between 
15-30 mL/minute; that dabigatran is suspended 36 or 72 hours 
before surgery with a low or high bleeding risk, respectively, 
in patients with a CrCl between 50-80 mL/minute; and that 
dabigatran is suspended 48 or 96 hours before surgery with 
a low or high risk of bleeding respectively, in patients with 
a CrCl between 30-50 mL/minute [2C].
New oral anticoagulants and laboratory tests 
The NOAC do not require routine monitoring 
through coagulation tests; in any case, global tests, 
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such as the PT and aPTT, are not useful for quantifying 
the anticoagulant effect of these new drugs and other 
quantitative tests are not yet available for routine use in 
all hospitals. Furthermore, POC instruments to determine 
the INR should not be used in patients being treated with 
NOAC. However, in emergencies (severe haemorrhage, 
thrombotic events, urgent surgery, liver or kidney failure, 
suspected overdose or pharmacological interactions) it 
may be necessary to quantify and have a rough idea of 
the anticoagulant effect of NOAC through the available 
coagulation tests; in these cases it is extremely important 
to know precisely when the drug was taken with respect 
to the blood sample, since the maximum effect of NOAC 
occurs at the time of their peak plasma concentration, 
which is reached 1-3 hours after drug intake114. Thus, for 
a correct clinical interpretation of the laboratory data, it 
is essential to know the type of drug taken, the dose and 
the time the last dose was taken. 
At present, there is still no definitive information 
on whether assays prior to taking the next dose (trough 
concentration) or at the time of the peak plasma 
concentration are better indicated. Analyses carried out in 
the USA by the Food and Drug Administration (FDA) on 
the phase III studies "Re-LY" and "ROCKET AF" showed 
that the trough drug level was correlated with clinical 
events. On the basis of this evidence, it has been proposed 
that controls should be performed before the patient takes 
the next dose of the drug (trough concentration).
Both first and second level clotting tests are variably 
affected by the different anticoagulant drugs. In general, 
it can be stated that the PT and chromogenic tests for 
assaying anti-FXa activity are more influenced by 
anti-FXa drugs (rivaroxaban, apixaban and edoxaban), 
whereas the aPTT, thrombin time, ecarin clotting time 
and ecarin chromogenic assay are more affected by drugs 
that inhibit thrombin (dabigatran). 
Two coagulation tests  for evaluating the 
anticoagulant effect of the direct inhibitors of thrombin, 
such as dabigatran, have so far been identified in the 
literature: the aPTT and the diluted thrombin time. 
Alterations of these tests can be indicative of an 
increased bleeding risk119,120. While the aPTT only 
provides a qualitative assessment and there is great 
variability between the different reagents on the 
market, the diluted thrombin time is able to provide 
a quantitative evaluation of the level of dabigatran 
present in the circulation and, considering its relative 
simplicity, should be used.
Table III - When to suspend treatment with new oral anticoagulants before surgery on the basis of the patient's renal function 
(determined by creatinine clearance [CrCl]) and bleeding risk (low or high, see Table II) associated with the 
surgical procedure. (Modified from Heidbuchel H et al.114)
CrCl (mL/minute)
Bleeding risk associated with the surgical procedure
New oral anticoagulants
Dabigatran Apixaban Rivaroxaban
Low High Low High Low High
≥80 ≥24 h ≥48 h ≥24 h ≥48 h ≥24 h ≥48 h
50-80 ≥36 h ≥72 h ≥24 h ≥48 h ≥24 h ≥48 h
30-50 ≥48 h ≥96 h ≥24 h ≥48 h ≥24 h ≥48 h
15-30 NI NI ≥36 h ≥48 h ≥36 h ≥48 h
<15 NI
CrCl: creatinine clearance; h: hours; NI: use of drug not indicated.
Table II  - Classification of elective surgical interventions 
divided according to bleeding risk. 
                  (Modified from Heidbuchel H et al.114)
Interventions  with a clinically unimportant risk of bleeding:
- dental interventions:
 - extraction of 1 to 3 teeth
 - paradontal surgery
 - abscess incision
 - implant positioning
- ocular interventions:
 - cataract or glaucoma
- endoscopy without surgery:
 - superficial surgery
 - abscess incision
 - small dermatological excisions
Interventions with a low risk of bleeding:
- endoscopy with biopsy
- prostate or bladder biopsy
- ablation for supraventricular tachycardia (including left-sided 
ablation via single trans-septal puncture)
Interventions with a high risk of bleeding:
- complex ablation 
- spinal or epidural anaesthesia; lumbar puncture
- thoracic surgery
- abdominal surgery
- major orthopaedic surgery
- liver biopsy
- transurethral resection of prostate
- renal biopsy
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The inhibitors of FXa, such as rivaroxaban, cause 
a prolongation of the PT although this provides only 
approximate information, given the wide variability of 
results depending on the type of reagent used121. 
An anti-FXa chromogenic test, using calibrators that 
are readily available on the market, has recently been 
developed. It is, however, important to clarify that, at 
present, these new tests (diluted thrombin time, for 
dabigatran, and anti-FXa activity assay, for the inhibitors 
of FXa) can provide plain information on the absence of 
the anticoagulant in the circulation, while there is not a 
clear, defined relationship between the circulating level 
and risk of bleeding or thrombosis. This aspect must be 
studied in the coming years. 
At present we know that the concentrations of 
the different oral anticoagulants can be measured 
using tests that are specific and sensitive for the 
individual compounds: these tests are simple, cheap 
and can be performed in all laboratories. We also 
know that information regarding the concentration 
of the anticoagulant drugs in the blood is useful 
for managing patients who are being assessed for 
particular clinical situations, such as urgent or elective 
surgery, invasive procedures, and haemorrhagic or 
thromboembolic complications. Furthermore, in the 
same way as for VKA, the results of these tests could 
be useful in the near future for determining threshold 
levels of anticoagulation above which surgery, invasive 
procedures and thrombolysis are contraindicated. 
Currently, one of the most important practical problems 
is the limited number of Italian laboratories able to 
carry out these specific tests; however, the growing use 
of NOAC and the consequent increase in the clinical 
needs of treated patients should lead to a progressively 
greater use of these tests in various different hospital 
settings.
No evidence-based recommendations can be 
made on the use of laboratory tests in the pre-operative 
evaluation of the anticoagulant effect of the NOAC. 
The management of patients with comorbidities related 
to altered haemostasis 
Patients with endocrine, metabolic or systemic 
diseases, such as FX deficiency in amyloidosis, can 
have altered haemostasis with a tendency to bleeding, 
similar to that in patients with congenital deficiencies 
of clotting factors122,123. The treatment strategy for these 
coagulopathies is frequently unclear.
It is suggested that the treatment of patients with 
altered haemostasis related to systemic, metabolic or 
endocrine diseases is established through consultation 
with an expert in haemostasis and thrombosis [2C].
Other drugs, besides antiplatelet agents and 
anticoagulants, such as selective serotonin reuptake 
inhibitors, valproic acid and Ginkgo biloba, can interfere 
with haemostasis, predisposing to bleeding.
Selective serotonin reuptake inhibitors have been 
associated with an increased tendency to bleed, due to 
depletion of serotonin from platelets124; however, the 
transfusion requirements of patients being treated with 
selective serotonin reuptake inhibitors who underwent 
major orthopaedic surgery or heart surgery were not 
increased125,126. 
In some cases valproic acid (an anti-epileptic 
drug) can lead to a reduction in the levels of some 
clotting factors [FVII, FVIII, FXIII, von Willebrand 
factor (vWF), fibrinogen], platelets, protein C and 
antithrombin127; however, these changes did not cause 
bleeding complications128,129. 
As far as concerns the extract of Ginkgo biloba, a 
meta-analysis of 18 randomised, controlled trials did not 
show an increase in bleeding associated with daily, oral 
intake of this medicinal plant130. 
It is suggested that treatment with selective serotonin 
release inhibitors is not routinely suspended in patients 
undergoing surgery [2B].
When selective serotonin reuptake inhibitors are used 
together with antiplatelet agents, it is suggested that the 
patient is assessed individually to define the strategy to 
adopt prior to surgery [2C].
In the case of surgery, it is suggested considering, 
on an individual basis and with specialist advice, the 
suspension of treatment with valproic acid, because this 
drug can promote bleeding [2C].
It is recommended that the use of Ginko biloba 
extract is not suspended in the case of surgical 
interventions [1B].
Management of the patient with a congenital bleeding 
disorder 
Defects of primary haemostasis
The most common congenital bleeding disorder is 
certainly that of hereditary deficiency of vWF, which 
has prevalence of 0.6-1.3% in the population13,131. The 
disease is due to either a lack of vWF or dysfunction 
of the protein and is classified into three types: type 1: 
partial quantitative defect; type 2: qualitative defect, 
of which there are four variants: 2A, 2B, 2M, and 
2N; and type 3: total lack of vWF. The acquired form 
of von Willebrand's disease (vWD) is the result of 
autoimmune and/or neoplastic disorders, or has a drug-
based aetiology132.
The bleeding tendency is a consequence of altered 
platelet adhesion because of a lack or dysfunction of 
vWF and/or reduced levels of FVIII13,131,132. 
Given that the laboratory diagnosis of vWD is 
complex, the laboratory tests must always be guided by 
the patient's clinical history and physical examination. 
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Additionally, there are questionnaires and bleeding 
scores that have been specifically designed to evaluate 
and quantify bleeding risk133-135. 
The prevention and management of bleeding in vWD 
is based on three treatment strategies: administration 
of desmopressin, which induces mobilisation of vWF 
from endothelial storage sites (stimulation therapy); 
administration of plasma-derived concentrates of vWF 
or vWF-rich FVIII (replacement therapy); administration 
of antifibrinolytics or platelet transfusions (haemostatic 
therapy). There are numerous national and international 
guidelines on this subject13,131,136-140. 
It is recommended that patients with vWD are 
managed in the pre-operative period in collaboration 
with an expert in haemostasis and thrombosis [1C].
It is recommended that criteria are used to define 
and evaluate bleeding risk in patients with vWD [1C].
It is recommended that patients with vWD who 
are to undergo minor surgery and are expected to have 
mild bleeding are given desmopressin, after a trial test, 
at doses explained in specific guidelinese (0.3 μg/kg 
diluted in 50 mL of saline solution and infused slowly, 
over more than 30 minutes) [1C]136-140.
It is recommended that patients with vWD who 
are to undergo major surgery and are expected to have 
clinically relevant bleeding are given replacement 
therapy with plasma-derived vWF or vWF-rich FVIII, 
using the treatment regimens explained in the specific 
guidelines [1C].
In patients with vWD who are to undergo major 
surgery, it is suggested that antifibrinolytics, as an 
adjuvant to more specific treatments, and platelet 
transfusions are used only in the case of failure of other 
treatments [2C].
In the context of disorders of primary haemostasis, 
platelet dysfunction is a diagnostic challenge. There 
does not seem to be a correlation between the severity 
of bleeding, the degree of vWF/platelet dysfunction and 
diagnostic laboratory tests, so that disorders of platelet 
function constitute a risk factor for bleeding rather than 
an unequivocal cause. 
The use of platelet function tests with the PFA 
100/200 cannot be recommended in patients with 
defects of primary haemostasis because of the poor 
sensitivity of the tests as well as false positive and false 
negative results141-143. 
The most common and least severe platelet disorders 
respond well to desmopressin, which shortens the 
bleeding time, whether used as prophylaxis or for the 
treatment of bleeding144-146. When used, the standard 
dose is 0.3 μg/kg, diluted in 50 mL of saline solution and 
infused slowly, over more than 30 minutes144.
Antifibrinolytics are useful as an adjunctive therapy 
in platelet disorders; small bleeds, such as those occurring 
in dental surgery, can respond well to these agents, even 
when used alone. The use of antifibrinolytic agents for 
the treatment of hereditary platelet disorders is not, 
however, based on evidence, although tranexamic acid 
(TXA) can partially correct the effects of clopidogrel 
on primary haemostasis142,144,147,148. 
In patients with hereditary disorders of platelet 
function, it is suggested that desmopressin is used for 
the prevention and control of bleeding, and that TXA is 
used as an adjuvant [2C].
The best known congenital platelet disorders are 
Glanzmann's thrombasthenia and Bernard-Soulier syndrome. 
These are characterised, respectively, by defective platelet 
aggregation and adhesion, due to alterations in platelet 
membrane glycoproteins (GP IIb/IIIa in Glanzmann's 
thrombasthenia and GP Ib-IX in Bernard-Soulier 
syndrome).
In most patients with these disorders, mild 
mucocutaneous bleeding responds to treatment with 
antifibrinolytic agents. However, the use of recombinant 
activated factor VII (rFVIIa) is indicated for surgery 
and invasive procedures (including dental extractions, 
sometimes), even if the technical data sheet states that it 
is indicated only for those patients with Glanzmann's 
thrombasthenia who have antibodies to GPIIb/IIIa 
and/or human leucocyte antigens or have become 
refractory to platelet transfusions149,150. 
When used, rFVIIa should be administered at a 
dose of 90 μg/kg, immediately before the intervention, 
repeated every 2 hours for the first 12 hours and, 
subsequently, every 3-4 hours until the bleeding risk 
has disappeared151. 
However, there are no universally accepted doses 
of rFVIIa defined for the various different settings of 
use. rFVIIa is not indicated in other forms of platelet 
disorders, for which platelet transfusions are necessary.
It is recommended considering the use of rFVIIa 
in patients with Glanzmann's thrombasthenia who are 
to undergo surgical interventions [1C].
In patients with Glanzmann's thrombasthenia or 
Bernard-Soulier syndrome undergoing elective, major 
surgery, it is suggested that platelet concentrates are 
transfused when other therapeutic options, including 
rFVIIa, do not guarantee a therapeutic effect [2C]142,145. 
It is suggested that the first doses of platelets are 
administered immediately before the intervention and 
further doses given after it, depending on clinical need [2C]. 
In cases of urgent surgery, single-unit platelet 
concentrates can be given, despite the awareness of 
the high risk of alloimmunisation and the consequent, 
subsequent limitation of response to this treatment145. 
As far as concerns treatment, the hereditary platelet 
disorders are considered moderate platelet disorders and, 
in the absence of platelet dysfunction, should be treated 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI
 Se
rvi
zi 
Srl
39
Blood Transfus 2016; 14: 23-65  DOI 10.2450/2015.0172-15
Patient Blood Managment
on the basis of the platelet count. Guidelines on platelet 
transfusions suggest a threshold of 50×109 platelets/L for 
major surgery or invasive procedures152-155 [liver biopsy, 
laparotomy, diagnostic lumbar puncture, insertion 
of central venous catheters (recent North-American 
guidelines suggest a threshold of 20×109 platelets/L 
for this last procedure)]155 and a threshold of 100×109 
platelets/L for neurosurgical or ophthalmological 
interventions152-154. However, there is still insufficient 
evidence to recommend a threshold for prophylactic 
transfusions in the peri-operative period in patients with 
hereditary platelet disorders. 
It is recommended that platelet transfusion are 
not used routinely in patients with hereditary platelet 
disorders [1C].
In patients with hereditary platelet disorders no 
evidence-based recommendations can be made 
concerning the threshold to adopt in the peri-operative 
period for prophylactic transfusion therapy with platelet 
concentrates. 
Defects of haemostasis related to clotting factor 
deficiencies
Congenital deficiency of FVIII and FIX in the plasma 
causes haemophilia A and haemophilia B, respectively.
The prevalence of haemophilia A in the population is 
1:10,000, while that of haemophilia B is 1:60,000. The 
clinical manifestations of haemophilia are spontaneous 
bleeding, mainly within joints, and excessive bleeding 
in the case of trauma and/or surgical interventions. 
The severity of the bleeding is related to the extent of 
the factor deficiency. Both forms of haemophilia are 
classified as mild, moderate or severe, depending on 
the level of FVIII or FIX present.
In the severe forms of haemophilia, replacement 
therapy can lead to the development of antibodies 
against FVIII or FIX, known as "inhibitors", a critical 
circumstance that requires various therapeutic strategies.
Anti-FVIII autoantibodies cause the bleeding 
disorder known as acquired haemophilia, which is rare 
condition characterised by a predisposition to potentially 
dangerous bleeding. This disorder is usually associated 
with cancer, autoimmune disorders, drugs or pregnancy.
The treatment of haemophilia is essentially 
replacement therapy with plasma-derived or recombinant 
concentrates of the deficient clotting factor (FVIII or 
FIX). Mild haemophilia A can also be treated with 
desmopressin and TXA, instead of replacement of the 
deficient factor with concentrates.
Despite the wide variability in the doses of 
concentrates used for the prophylaxis or treatment of 
bleeding, in the case of surgery, the World Federation of 
Haemophilia recommends that the levels of the deficient 
factor are 80-100% in the pre-operative period156; it 
also recommends that the levels are maintained around 
60-80% in the first 3 days after the operation, around 
40-60% for the next 3 days and around 30-50% in the 
second week after surgery.
In the case of haemophilia B, the recommended factor 
levels are slightly lower: 60-80%, 40-60%, 30-50% and 
20-40%, respectively140,156-162.
In conclusion, the recommendations for the 
management of patients with haemophilia or other 
congenital bleeding disorders are the following.
Collaboration with an expert in haemostasis and 
thrombosis is recommended during the planning of the 
surgical intervention [1C].
It is recommended that adequate replacement 
therapy is given during the peri-operative period [1C].
It is suggested that guidelines on how to perform 
replacement therapy (target level of deficient factor and 
duration of treatment) are followed for patients who are 
candidates for elective surgery [2C].
With regards to replacement therapy in the peri-
operative period, it is recommended that either 
recombinant or plasma-derived concentrate is used [1C].
In the presence of inhibitor, treatment with rFVIIa 
or activated prothrombin complex concentrate (PCC), 
i.e. a factor eight inhibitor bypassing agent (FEIBA), is 
suggested [2C].
A recent, prospective study carried out on 24 
haemophilic patients undergoing orthopaedic surgery 
showed the presence of subclinical deep vein thromboses 
in over 10% of cases. On the basis of these results, 
antithrombotic prophylaxis could also be indicated 
in haemophilic patients, in individual cases. Many 
Haemophilia Centres in Europe use pharmacological 
antithrombotic prophylaxis after orthopaedic surgery163. 
For haemophiliacs undergoing major surgery, it is 
suggested that peri-operative thromboprophylaxis is 
individualised [2C].
Congenital deficiencies of clotting factors other than 
FVIII and FIX are very rare and have a prevalence of 
between 1:500,000 and 1:2,000,000164; the prevalence 
of autosomal dominant FXI deficiency is 1:30,000, but 
the most common of these deficiencies is that of FVII. 
The levels of evidence on treatment of these 
deficiencies are low (descriptive studies and experts' 
opinions) and data on pre-operative prophylactic therapy 
are scarce.
In cases of major surgery in patients with FVII 
deficiency, the proposed threshold for replacement 
therapy with FVII concentrate is 10% of the normal 
plasma level164-166. Above this level replacement therapy 
does not seem to be necessary, as demonstrated by a 
retrospective analysis of surgical procedures conducted 
without giving such therapy and during which the 
frequency of bleeding events was 15%167. 
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rFVIIa is the treatment of choice for congenital FVII 
deficiency; if this is not available, a plasma-derived 
concentrate of FVII is preferable to PCC, because of the 
potential prothrombotic effect of the latter140,164.
In congenital FVII deficiency, as an alternative to 
rFVIIa, it is suggested that a plasma-derived concentrate 
of FVII is used at the dose of 10-40 IU/kg [2C]164.
In patient with congenital FVII deficiency who are to 
undergo major surgery, it is suggested using a dose of 
rFVIIa of 15-30 μg/kg every 4-6 hours, usually giving 
at least three doses [2B]164. 
In cases of congenital deficiency of fibrinogen or 
FXIII the British guidelines recommend using specific 
concentrates164. Replacement therapy is indicated 
in hypofibrinogenaemia when the concentration of 
fibrinogen is <1 g/L or <20-30% of normal. However, 
the possible risk of thrombosis must be kept in mind 
when using plasma-derived concentrates.
Fresh-frozen plasma, preferably industry-produced 
and virus-inactivated, is the only therapeutic option in 
patients with congenital FV or FXI deficiency164. There 
is a plasma-derived concentrate of FXI on the market, 
but it is not currently available in Italy. Patients with FXI 
deficiency and inhibitors have been treated with success, 
on the occasion of surgery, with low doses of rFVIIa 
(33-47 μg/kg)168; contemporaneous administration of 
TXA has also been demonstrated to be effective in 
controlling bleeding164.
PCC are the reference concentrates for deficiencies 
of FII and FX, for which specific concentrates are not 
available164,169,170. 
In patients with other clotting factor deficiencies, no 
evidence-based recommendations can be made on 
the peri-operative use of rFVIIa, desmopressin or TXA. 
Management of patients with acquired platelet disorders
To reduce the risk of bleeding associated with major 
surgery or invasive procedures in patients with acquired 
platelet disorders, it is suggested that a prophylactic 
transfusion of platelet concentrates is given if the platelet 
count is below the threshold of 50×109 platelets/L 
[2C]152-155.
It is suggested that the first doses of platelets are 
given immediately before the operation and further doses 
after it, depending on the clinical need [2C]. 
Intra-operative period
Autologous transfusion techniques
Acute normovolaemic haemodilution
Acute normovolaemic haemodilution is a type of 
autologous transfusion introduced in the 1970s171-173. 
It consists in removing at least three or four units of 
autologous blood, maintaining isovolaemia, immediately 
before elective surgery174. Acute normovolaemic 
haemodilution is usually performed after induction of 
anaesthesia175, just before the surgical incision176. The 
circulating blood volume is maintained by infusing 
crystalloids, administering 2-3 mL for every mL of blood 
removed, or colloids, in a ratio of 1:1 with the volume 
of blood removed174. 
The efficacy of acute normovolaemic haemodilution 
in reducing the need for allogeneic red blood cell 
transfusion is, however, doubtful177. Various studies, 
including prospective, randomised trials, showed that 
it could reduce recourse to allogeneic transfusion 
therapy in patients undergoing elective heart surgery, 
orthopaedic operations (knee replacement), abdominal, 
vascular, urological, maxillofacial, or liver surgery and 
in patients undergoing surgery because of burns178-189. 
However, other studies did not find any substantial 
benefit or even found an increased need for allogeneic 
transfusions190-192. 
The lack of real benefits from this procedure and 
the increased risk of requiring transfusion therapy, 
including allogeneic transfusions, were demonstrated 
by some meta-analyses193-196 and confirmed by a recent 
study evaluating the efficacy of autologous transfusion 
techniques, based on mathematical models76. Other 
pharmacological strategies for conserving blood, such 
as the use of TXA, have been found to be more effective 
than acute normovolaemic haemodilution in limiting 
the use of allogeneic red blood cell transfusions195,197. 
Finally, the reduction of overall bleeding is minimal, 
there is an increase in intra-operative bleeding 
(heart, liver and thoracic surgery), the relative risk 
of re-operation because of bleeding is increased and 
there is a lack of information on the safety of the 
procedure195,198,199. 
The routine use of acute normovolaemic haemodilution 
as a (single) technique to reduce allogeneic transfusion 
requirements is not recommended [1A]. 
Intra-operative blood recovery
Intra-operative blood recovery is a method of 
saving blood in which blood lost in the surgical field 
is re-used. This blood is aspirated and anticoagulated 
before passing into a collection reservoir and from there, 
through microaggregate filters of varied diameter, into 
the bowl of a specific cell separator, to be concentrated 
by centrifugation and then washed with physiological 
saline before being re-infused back into the patient200. 
Intra-operative blood recovery is indicated in many 
types of elective and urgent surgery, when the blood 
loss is expected to be at least 1,000 mL or ≥20% of the 
patient's circulatory volume200,201. 
The meta-analyses currently available show that 
intra-operative blood recovery significantly reduces the 
need for allogeneic red blood cell transfusions in patients 
undergoing elective surgery202-204. A study published 
in 2013 evaluating the efficacy of autologous blood 
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transfusion techniques, based on mathematical models, 
indicated that this is the most effective and efficient 
of such tecniques76. However, a recent randomised, 
controlled trial, carried out in the specific setting 
of elective lower limb joint replacement surgery in 
patients with pre-operative Hb concentrations above 
130 g/L, found that intra-operative blood recovery, like 
post-operative blood recovery, not only did not reduce 
transfusion needs, but increased costs205. 
It is recommended that intra-operative blood 
recovery is used in major orthopaedic surgery, including 
vertebral column surgery206-212, only in cases in which 
blood loss is expected to be at least 1,000 mL or in any 
case ≥20% of the patient's circulatory volume despite 
adopting multimodal strategies, including the use of 
blood-conserving techniques (pharmacological, surgical 
and anaesthesiological), and taking into account both the 
characteristics of the individual patient (bleeding risk, 
multiple alloimmunisation) and the experience of the 
surgical and anaesthetic teams [1B]199. 
Blood-saving surgical techniques 
The greater the expected blood loss, the stronger 
the advice to use multiple mehtods, appropriate 
for the clinical circumstances, to reduce bleeding. 
The use of appropriate combinations of methods 
has a synergistic effect on reducing blood losses. 
Meticulous haemostasis and surgical technique are 
essential. The haemostasis must be achieved through 
a combination of methods, starting from the surgical 
approach, which must have the least traumatic impact 
possible, with well-planned surgical exposure, arriving 
through the least vascularised tissue planes and with 
atraumatic management of the tissues213. Furthermore, 
immediately before the surgical incision, a dose of local 
anaesthetic and adrenaline can be given at the incision 
site in order to obtain rapid, localised vasoconstriction. 
The duration of the intervention must be minimised 
and, in cases of complex procedures in which repeated 
surgery is necessary, particularly in patients with 
multiple trauma, surgery should be fractionated and 
conducted in stages214. 
In the intra-operative phase the surgeon has various 
instruments available to achieve perfect haemostasis, 
such as monopolar or bipolar electrocautery devices, 
ultrasound cautery probes and argon coagulators; these 
last two are not commonly used in orthopaedic surgery 
and are mainly reserved for very selected cases, in 
particular patients with cancer215. 
As far as concerns knee arthroplasty, although special 
surgical techniques and instruments, which avoid violation 
of both the tibial and femoral intramedullary canals and, 
therefore, minimise blood losses, were introduced only 
recently, their use has become consolidated216. However, 
given the notable pre-operative organisation and greater 
consumption of resources associated with the sue 
of these "custom-fit" methods, they are reserved for 
selected cases; their routine use is also avoided because, 
at present, there are no studies demonstrating their 
long-term efficacy in terms of functional outcomes 
and, furthermore, a recent meta-analysis did not show 
that they produce an overall improvement in surgical 
efficiency or that they are cost-effective217. 
A survey by the American Association of Hip and 
Knee Surgeons found that a tourniquet is often used 
during total knee replacement: the tourniquet must 
be applied to the root of the limb to be operated 
only in certain stages of the surgical procedure and 
after complete "squeezing" of the limb218. However, 
some studies have associated tourniquet use with 
complications such as cutaneous or muscular damage, 
rhabdomyolysis, neurological damage, post-operative 
stiffness, deep vein thrombosis and pulmonary 
embolism219,220. Furthermore, a recent meta-analysis 
provided some evidence that the use of a tourniquet 
can increase post-operative complications and reduce 
the range of movements in the early post-operative 
period, that it does not reduce total blood loss 
significantly or the need for transfusion therapy, but 
only decreases intra-operative bleeding221. In contrast, 
another meta-analysis showed that application of a 
tourniquet could reduce total blood losses, lower the 
incidence of transfusions and shorten the duration of 
the operation, although the same analysis indicated 
some possible disadvantages and complications 
associated with tourniquet use222.
With the purpose of containing intra-operative 
bleeding effectively during elective arthroplasties, it is 
suggested that combinations of surgical techniques and 
instruments (considered appropriate for their synergistic 
effect on reducing blood losses also on the basis of 
the surgical team's experience) are used in order to 
minimise trauma to tissues and vessels and promote 
local haemostasis, which can also be aided by local 
administration of vasoconstrictive drugs [2C].
Given the possible post-operative complications and 
the controversial effect on reducing transfusion needs, 
no evidence-based recommendations can be made 
concerning the routine use of a tourniquet as a blood-
conserving technique in elective prosthetic joint surgery. 
Infusion fluids
The correction of bleeding-induced hypovolaemia 
by infusion of crystalloids and/or colloids is a priority 
in the management of patients with acute or subacute 
bleeding and is the first alternative to allogeneic 
transfusion, because acute hypovolaemia is less well 
tolerated than anaemia27. Adequate restoration of the 
circulatory volume and, consequently, the cardiac 
output, enables oxygen transport to the tissues to 
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be maintained. However, the best fluid replacement 
strategy in patients with critical bleeding is still the 
subject of debate223. 
Crystalloid and non-protein-containing colloid 
solutions are the treatment of first choice199,224. 
Isotonic 0.9% saline solution, Ringer's solution and 
other balanced saline solutions, such as Ringer's 
lactate, are those most commonly used at the moment. 
They are cheap and do not alter haemostasis or 
renal function27. However, the choice of fluids to 
administer intravenously during surgical procedures 
and in critically ill patients is dictated more by 
clinical practice than by solid evidence225. The 
debate on the choice of fluid has concentrated mainly 
on evaluating differences in outcomes depending 
on whether crystalloid or colloid solutions are 
used. Recently, however, there has been interest in 
differences in outcomes in relation to the chlorine 
content in crystalloid solutions. In fact, new notions 
on the conventional Starling's model, regarding 
microvascular fluid exchange, indicate that the 
efficacy of colloids in restoring and maintaining 
depleted intravascular volume is only moderately 
greater than that of crystalloids. Various very recent 
randomised controlled trials have demonstrated that 
the modest improvements in certain physiological 
end-points, obtained in the short-term with colloids, 
do not translate into a better outcome for the individual 
patient. Furthermore, there is substantial evidence that 
some types of fluids (solutions of hydroxyethyl starch 
and of albumin) can even have a negative effect on 
some outcome markers when administered to selected 
populations of patients.
The most commonly used colloids are the protein-
free ones, such as solutions of hydroxyethyl starch 
or gelatine, and solutions of human albumin (natural 
colloid)27. Given their low molecular weight, gelatine 
solutions have a short intravascular half-life (2-3 hours) 
and a limited capacity to expand plasma (70-80%). 
Solutions of 6% hydroxyethyl starch have a longer 
half-life (6-8 hours) and a greater capacity to expand the 
plasms (80-120%) and are, therefore, the colloids most 
widely used at present for expanding blood volume; 
however, when used as volume expanders to correct 
acute hypovolaemia in patients with haemorrhagic 
shock, they can increase the risk of mortality and renal 
failure226. Furthermore, massive use of high molecular 
weight hydroxyethyl starch solutions can cause 
alterations of haemostasis characterised by impaired 
platelet function88,199. Finally, following a review, 
performed for safety reasons, of the indications for the 
use of hydroxyethyl starch solutions, restrictions have 
been applied to the duration of treatment, which must 
be limited to the initial phase of volume restoration, for 
a maximum of 24 hours. Furthermore, the following 
monitoring is expected: a) continuous haemodynamic 
monitoring; b) electrolytes and fluid balance; c) renal 
function, for at least 90 days; d) clotting parameters, in 
the case of repeated administrations227. 
Albumin 5% has the capacity to expand the plasma 
volume by 75% of the volume infused27; its clinical 
effects, in terms of morbidity and mortality at 28 days, 
are the same as those of isotonic saline 0.9% when used 
to restore circulatory volume in patients in intensive 
care228. For this reason, solutions of albumin 5% should 
be used as second-line treatment when crystalloid or 
non-protein colloid solutions have already been used at 
maximum doses, without having produced an adequate 
clinical response, and when non-protein colloids are 
contraindicated199.
In order to correct bleeding-induced hypovolaemia, 
as a pharmacological alternative to improve oxygen 
transport, it is recommended that crystalloid or protein-
free colloid solutions are used as the treatment of first 
choice, with albumin 5% as second-line therapy, when 
crystalloid or non-protein colloid solutions have already 
been used at maximum doses, without having produced 
an adequate clinical response, and when non-protein 
colloids are contraindicated [1A].
It is recommended that hydroxyethyl starch 
solutions are not used to correct acute hypovolaemia 
in bleeding patients because of the increased risk of 
mortality and renal failure [1B]. 
It is recommended that high molecular weight 
hydroxyethyl starch solutions are not used, in order to 
avoid haemostatic alterations characterised by impaired 
platelet function [1B]. 
Patients with moderate bleeding
Patients with limited or moderate bleeding (<30% 
of circulatory volume or <1,300 mL), who are not at 
risk of further bleeding, can be treated with infusions 
of crystalloid solutions27,199,229, reserving the non-protein 
colloids for subjects with haemodynamic instability199,224.
With the purpose of limiting transfusion support in 
patients with moderate bleeding, it is recommended 
that the patient's circulatory volume is first restored 
using crystalloid or non-protein colloid solutions [1C].
Patients with severe bleeding
Patients with severe bleeding (30-40% of circulatory 
volume) can initially be treated with crystalloid 
solutions27,199,229. Small volumes of Ringer's lactate can 
help to maintain a systolic pressure of 80-90 mmHg 
(controlled hypotension)230. However, after the initial use 
of moderate volumes of crystalloids, it is justifiable to 
add non-protein colloids or vasoactive drugs. Once the 
circulatory volume has been restored, the possible need 
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for transfusion can be evaluated based on laboratory 
parameters and estimated blood losses27,199. 
With the purpose of limiting transfusion support in 
patients with severe bleeding, it is recommended that 
the patient's circulatory volume is first restored using 
crystalloid or non-protein colloid solutions [1C].
Patients with life-threatening bleeding
Patients with life-threatening bleeding (>40% 
of circulatory volume) who do not respond to 
initial treatment with 2 L of fluids, have instable 
haemodynamics or are bleeding at a rate ≥50 mL/minute, 
require transfusion of red cell concentrates, which can 
be a potentially life-saving therapy27,199.
Massive transfusion protocols based on the use of 
fixed blood component ratios, derived from experience 
in the military setting, are not currently supported by 
solid evidence and have important limitations caused by 
a survival bias27,231. For this reason, until new evidence 
is available, the traditional therapeutic approach, 
based on restoring circulatory volume, monitoring 
haemostasis and other laboratory parameters and 
providing transfusion support with the appropriate blood 
component, should be considered valid for the majority 
of bleeding patients27,199.
The use of POC instruments for global monitoring 
of haemostasis of whole blood can facilitate an 
individualised approach to the required transfusion 
support and, in some cases, enable the use of fresh-frozen 
plasma to be reduced27,231. 
For specific recommendations on the use of POC 
instruments, refer to the section dedicated to this subject.
With the purpose of limiting transfusion support in 
patients with life-threatening bleeding, it is suggested 
that the patient's circulatory volume is initially expanded 
with crystalloid or non-protein colloid solutions, 
followed by transfusion therapy with blood components 
and, if necessary, with plasma-derived medicinal 
products [2B].
Dosing infusion fluids
The starting dose of crystalloids (preferably 
Ringer's lactate solution), to infuse at the rate of 
60-80 mL/kg/hour to maintain a systolic pressure of 
about 80-90 mmHg, is 3 mL per mL of blood loss27,230.
The initial dose of colloids is 1 mL per mL of blood 
loss27,230.
Haemostatic agents for topical use
The haemostatic agents for topical use include blood 
components, such as fibrin glue, and medical devices.
Fibrin glue is a blood component for topical use that 
has been exploited in surgery for more than 20 years199; its 
main components are fibrinogen, FXIII, thrombin (and 
calcium chloride with or without antifibrinolytics) which 
can be applied contemporaneously or in succession on 
the surfaces to be treated. The application of fibrin glue 
reproduces, in situ, the final stage of the coagulation 
cascade mediating the activation of fibrinogen by 
thrombin199. Given its haemostatic potential, this blood 
component for topical applications has been used with 
the aim of reducing allogeneic transfusion requirements 
in various surgical settings, despite its high cost. 
However, its efficacy in controlling bleeding was found 
to be greatest in orthopaedic surgery232.
In contrast, medical devices act through a mechanical 
or physical effect. Examples include cellulose or gelatine 
granules which, when saturated with blood, swell until 
forming a mass which reduces bleeding by mechanical 
compression. 
The various haemostatic agents for topical use have 
overlapping clinical indications. Some products are 
indicated to facilitate haemostasis (Floseal®, Sivek®, 
Tabotamp®, and Curaspon Standard®), others, including 
fibrin glue, are also indicated to seal tissues and support 
sutures (Beriplast®, Quixil®, Tachosil®, Tisseel®, 
Tissucol®, Coseal®, and Glubran®)233. However, some 
issues have emerged from the analysis of the efficacy 
and safety of these products, mainly because of the 
lack of solid evidence derived from well-performed, 
randomised studies234.
It is suggested that fibrin glue is used to promote 
local haemostasis and as a complementary method to 
limit intra-operative use of blood, on the basis of local 
protocols that take into consideration the characteristics 
of the individual patient (bleeding risk, multiple 
alloimmunisation), the type of operation, the experience 
of the surgical and anaesthetic teams, as well as the 
possibility of combining this blood component with 
other blood-saving strategies, taking into account the 
cost-efficacy ratio [2B].
No evidence-based recommendations can be made 
on the routine use of haemostatic medical devices for 
topical use in elective orthopaedic surgery.
Blood-conserving anaesthesiological techniques
Various studies have demonstrated that neuroaxial 
anaesthesia (epidural and subarachnoid) can be 
associated with a significant reduction in bleeding, 
especially if used during orthopaedic operations,235,236. 
The data are not, however, unanimous because a 
meta-analysis concerning patients undergoing total 
knee replacement did not show significant differences 
depending on whether neuroaxial or general anaesthesia 
was used237. Nevertheless, it does seem that neuroaxial 
anaesthesia can reduce transfusion requirements because 
of the relative systemic hypotension associated with 
the technique which is due to sympathetic nervous 
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system blockade and a consequent reduction in 
venous tone. This effect is, however, variable and 
its magnitude is not always predictable. In fact, 
there is not a good correlation between the dose of 
anaesthetic administered and the effect on blood 
pressure, because of the variations in blood pressure 
induced by the different level of nervous blockade 
obtained238. 
Besides neuroaxial anaesthesia, lumbar plexus 
blockade was also associated with a reduction 
of both intra-operative blood loss (22%, 310 mL 
compared to 617 mL) and total blood loss (45%, 712 
mL compared to 1,074 mL), when used in patients 
undergoing prosthetic hip surgery239,240. 
As far as concerns general anaesthesia, the use of 
completely intravenous propofol-based anaesthesia 
is associated with a decrease in blood loss in spinal 
surgery241. 
However, studies comparing blood losses related 
to various different anaesthesiological techniques 
in orthopaedic surgery should be interpreted with 
care, since most were conducted in a period in which 
more liberal transfusion practices were adopted 
compared to those currently in use. Furthermore, it 
is possible that additional blood-sparing techniques 
(such as peri-operative blood recovery) can reduce 
or even annul the advantages of using neuroaxial 
techniques of anaesthesia. Nevertheless, despite 
these limitations, it can be expected that these latter 
may reduce surgical bleeding, at least in selected 
subgroups of patients.
As far as concerns body temperature, it is now 
well established that this is related to the degree of 
transfusion support. Hypothermia during surgical 
procedures is produced by a combination of 
different factors which participate in the loss of 
body heat (low temperature in the operating theatre, 
administration of fluids that have not been warmed, 
changes in the mechanisms of thermoregulation 
induced by the anaesthesia and evaporation 
from body cavities in the case of abdominal or 
thoracic surgery). A drop, even moderate, in body 
temperature is able to affect the physiological 
mechanisms of haemostasis, modifying platelet 
function and inhibiting the temperature-dependent 
enzyme reactions of coagulation. It has been shown 
that even mild hypothermia (a decrease of <1 °C in 
the body temperature) can increase blood losses by 
as much as 16%, with a related increase in the risk 
of receiving transfusion therapy (22%)242-244. 
The choice of anaesthetic technique in 
orthopaedic surgery must take into account the 
potential benefit of regional techniques in limiting 
transfusion requirements; anaesthetists should 
be aware that regional anaesthesia in spontaneously 
ventilated subjects may have advantages in terms of 
transfusion requirements (by decreasing blood loss). 
It is suggested that loco-regional anaesthetic 
techniques are used, depending on the experience of 
the anaesthetic team, with the aim of contributing to 
limiting intra-operative blood loss [2C].
It is essential that body temperature is monitored 
during surgery. 
It is recommended that hypothermia is prevented, 
and treated if it occurs, by pre-warming infusion 
fluids and warming the patient; the purpose is to 
limit intra-operative bleeding, as well as for obvious 
reasons of comfort [1C].
Pharmacological techniques and haemostatic agents
Drugs to reduce surgical bleeding and transfusion 
needs in surgery can be used both in prevention and 
correction of any disorders of haemostasis in the peri-
operative period. Recently the indications for the use 
of individual clotting factor concentrates (fibrinogen, 
rFVIIa) or combinations (PCC) have been extended 
to surgical patients with life-threatening bleeding, 
although solid confirmation of the evidence is still 
required88. 
Recent data confirm the central role of fibrinogen 
in the formation of stable clots. In this regard, there are 
emerging data from both randomised and prospective 
cohort studies, carried out in various clinical settings, 
indicating that optimisation of coagulation through 
administration of fibrinogen concentrate is associated 
with reductions in peri-operative bleeding and 
transfusion support245-247.
A recent meta-analysis showed the clinical and 
statistical heterogeneity of the trials included and 
highlighted that it was impossible to classify the trials as 
being "at low risk of bias"; the meta-analysis confirmed 
the statistically significant reduction in allogeneic 
transfusion support but did not show any effect on the 
other pre-defined outcomes, including mortality and 
bleeding248. However, an update of the abovementioned 
meta-analysis249 did find a statistically significant 
reduction of bleeding, mainly in elective heart surgery, 
while reiterating the lack of demonstrated efficacy on 
mortality and the need for caution when extrapolating 
results to other settings such as trauma and obstetrics. 
In fact, the increasing use of fibrinogen concentrates 
is supported mainly by observational studies with 
substantial methodological limitations which do not 
currently justify the routine administration of these 
concentrates.
The usefulness of determining the pre-operative 
concentration of plasma fibrinogen, according to the 
Clauss method, has been highlighted250,251. The liver 
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produces from 2 to 5 grams/day of fibrinogen and 
guarantees mean plasma levels between 2 and 4.5 g/L252. 
Fibrinogen concentrate has been demonstrated to 
have a better cost/benefit ratio in clinical use when the 
indication comes from monitoring coagulation through 
thromboelastographic methods88,199,253. 
In patients with congenital deficiency of fibrinogen, 
levels of fibrinogen in the blood below 1 g/L are 
considered critical164,166,254. 
I n  con t r a s t ,  i n  pa t i en t s  w i th  acqu i r ed 
hypofibrinogenaemia, the critical levels of fibrinogen, 
in the presence of massive bleeding, are more 
controversial and supported mainly by guidelines rather 
than evidence deriving from randomised studies248,249,255. 
In fact, two guidelines published in 2013 indicate that 
trigger levels of fibrinogenaemia in the presence of 
massive haemorrhage are <1.5-2 g/L88,256, while five 
earlier recommendations, published between 2006 and 
2011, indicate levels <0.8-1 g/L199,257-260. Similarly, 
recommended target levels of plasma fibrinogen are 
>1 g/L261 or between 1.5 and 2 g/L259.
Plasma-derived fibrinogen concentrates have a 
consolidated and privileged role, with respect to fresh-
frozen plasma and cryoprecipitate, in the treatment 
of bleeding related to a congenital deficiency of this 
clotting factor164,166,254. The use of this plasma-derived 
medicine is also increasing in the setting of bleeding due 
to acquired deficiencies, in part because of the numerous 
advantages it has compared to the use of allogeneic blood 
components. In fact, fibrinogen concentrate is safer, 
not only with regards to infection risk, and there are no 
problems of ABO incompatibility with the recipient; 
furthermore, fibrinogen concentrate enables replacement 
therapy to be delivered with much smaller volumes (200 
mL per 4 grams of fibrinogen) compared to fresh-frozen 
plasma or cryoprecipitate255.
Data on the use of fibrinogen in elective orthopaedic 
surgery are very limited. The effect of fibrinogen 
concentrate was analysed retrospectively in a cohort 
of nine paediatric patients with craniosynostosis262 and 
prospectively in 66 patients treated with crystalloids or 
colloids during major orthopaedic surgery263. In both 
studies, the administration of fibrinogen had favourable 
effects on the dynamics of clot formation and on clot 
strength.
For specific recommendations on the use of 
fibrinogen, refer to the paragraph on POC instruments.
In recent years there has been an increase in off-label 
use of rFVIIa for the treatment of critical bleeding in 
surgical patients264,265. However, a systematic Cochrane 
review recommends that rFVIIa is used exclusively 
in the context of clinical trials266. When used, the 
suggested dose is 90-120 mg/kg, repeated if necessary, 
after correction of some abnormalities, such as 
hypofibrinogenaemia, thrombocytopenia, hypothermia, 
acidosis and hyperfibrinolysis88. 
For specific recommendations on the use of 
rFVIIa, refer to the paragraph on POC instruments.
The main indication for the use of non-activated PCC 
is neutralisation of the anticoagulant effect in patients 
receiving oral treatment with VKA or NOAC, while 
activated PCC (FEIBA) are used in the treatment of 
patients with inhibitors of clotting factors and, recently, 
have also been suggested for use in patients being treated 
with NOAC. Thus, PCC, activated or not, are used 
both in cases of severe bleeding and in cases of urgent 
surgery. These plasma-derived medicinal products have, 
in fact, been demonstrated to be useful in preventing 
or treating bleeding in the presence of peri-operative 
coagulopathy88. 
For specific recommendations on the use of PCC 
refer to the section on monitoring patients and 
management of post-operative bleeding.
Fibrinolysis is an important cause of bleeding in 
surgical patients. There are some types of surgery (total 
knee replacement with a tourniquet, cardiopulmonary 
bypass, liver transplantation) which are more frequently 
associated with fibrinolysis and, therefore, benefit more 
than others from the use of TXA. Systematic reviews of 
randomised controlled trials indicate that the use of TXA 
has a significant impact, reducing transfusion support, 
particularly in cardiac and orthopaedic surgery, and 
indicate that the use of this drug is effectively associated 
with reductions in both the number of patients transfused 
and in their transfusion requirements88,267,268. As far as 
concerns the dose of TXA in major orthopaedic surgery, 
a meta-analysis showed that the reduction in the risk 
of receiving red blood cell transfusions is independent 
of the total dose of TXA administered269. Similarly, 
the timing of the administration of TXA, that is, at 
induction of anaesthesia rather than before release of 
the tourniquet, does not seem to affect the efficacy or 
safety of the treatment267. 
It is suggested that intravenous TXA is administered 
in hip and knee replacement surgery (as well as in major 
surgery of the spinal column) [2A]270-278.
The most frequently used doses of TXA are as 
follows: total hip or knee replacement surgery, a starting 
dose of 10-15 mg/kg before surgery, followed or not by 
an infusion of 1 mg/kg/hour for 4-6 hours or repetition 
of the initial dose in the post-operative period; surgery 
to the spine, a starting dose of 20-100 mg/kg, followed 
by an infusion of 10 mg/kg/hour for 4-6 hours27. 
Since there are reports of a state of hypercoagulability 
being induced in some patients (subjects with a past 
history of thromboembolic events, those aged over 60 
years, females, those undergoing hip trauma surgery 
or cancer surgery), it is suggested that the risks and 
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benefits of TXA are analysed carefully before its use 
[2C]279. 
TXA applied topically, also in combination with 
intravenous administration280, has been found to be safe 
and effective in containing transfusion requirements in 
elective hip and knee surgery281-290 and does not cause 
adverse biomechanical effects on the prostheses used291.
It is suggested that TXA is used topically, also in 
combination with intravenously administered TXA, in 
patients undergoing elective hip or knee arthroplasty [2B].
It is suggested that TXA is used only by the topical 
route in patients undergoing elective hip or knee 
arthroplasty who have risk factors for hypercoagulability 
according to the pre-operative history [2B].
Point-of-care testing
Since the decision to transfuse red cell concentrates 
in the peri-operative period is based in part on the 
patient's Hb concentration, the availability of rapid, 
reliable measurements of this parameter, with POC 
instruments, increases the safety of transfusion and 
optimises this therapeutic intervention88,292. 
It is recommended that POC instruments acquired 
and used measure the concentration of Hb and the 
haematocrit without needing dilution of whole blood 
in the pre-analytic phase [1C]. 
The POC instruments for monitoring haemostasis 
use whole blood292 and can be employed not only in 
transfusion facilities and laboratories, but also in the 
Accident and Emergency Department and operating 
theatre, guaranteeing shorter performance times than 
those of standard laboratory tests88. 
The main POC instruments that can be used for global 
monitoring of haemostasis are the thromboelastograph 
(TEG) and the thromboelastometer (ROTEM). These 
rapidly produce results in both numerical and graphical 
form and are able to detect the anticoagulant effect of 
acidosis or hypothermia and hyperthermia, since they 
can be used in a range of body temperatures between 
22 °C and 42 °C; furthermore, they can pick up and 
quantify thrombocytopenia, clotting factor deficiencies, 
the effect of heparin, hypofibrinogenaemia and 
hyperfibrinolysis293.
Although a recent systematic Cochrane review showed 
that the use of TEG and ROTEM to monitor haemostasis 
in patients with massive bleeding does not have significant 
advantages in terms of morbidity and mortality compared 
with the use of standard laboratory tests294, these POC 
instruments are widely used in elective surgery, in heart 
surgery and, in particular, in liver transplantation and in 
elective major orthopaedic surgery to guide replacement 
therapy with clotting factors (with plasma or fibrinogen 
concentrate)27,245,246,295-299, or to monitor hyperfibrinolysis 
and to evaluate the possible use of TXA300.
One limitation of the TEG is its incapacity to evaluate 
platelet function adequately27,301. 
It is suggested that POC instruments (TEG and 
ROTEM) are used to monitor overall haemostasis with 
the purpose of guiding clotting factor replacement 
therapy and to limit the use of transfusion support with 
blood components in elective major orthopaedic surgery 
with a high risk of bleeding or in the presence of major 
bleeding [2A].
It is suggested that the concentration of fibrinogen 
is measured pre-operatively using the Clauss method 
[2C]199,250.
In the presence of massive bleeding during elective 
major orthopaedic surgery and in association with the 
correction of the triggering cause, it is suggested that 
severe hypofibrinogenaemia (<1 g/L) which persists 
despite treatment with fresh-frozen plasma should be 
treated with fibrinogen concentrate (or, if not available, 
with cryoprecipitate) [2C].
In the same conditions and during massive 
transfusion, it is suggested that treatment with 
fibrinogen concentrate is considered when the level of 
fibrinogenaemia is <1.5 g/L, to prevent the fibrinogen 
level from falling below 1 g/L, the critical threshold 
for haemostasis [2C].
It is suggested that the administration of fibrinogen 
is privileged over that of fresh-frozen plasma (or 
cryoprecipitate) when there are contraindications to 
volume overloading [2C].
It is suggested that an initial dose of 25-50 mg/kg of 
fibrinogen concentrate is administered [2C].
rFVIIa is indicated for the treatment of patients 
with haemophilia with inhibitors, those with congenital 
deficiency of FVII and patients with Glanzmann's 
thrombasthenia. However, it has also been widely used 
to control bleeding in off-label settings, such as trauma, 
heart surgery, liver surgery, post-partum and cerebral 
haemorrhage.
Although rFVIIa has been demonstrated to 
have variable effects on morbidity and transfusion 
requirements, a definitive effect on mortality has 
not been observed and, for this reason, there is not 
a clear indication for its use, particularly in elective 
surgery256,265,302-304. Furthermore, there have been recent 
reports of side effects, especially arterial and venous 
thromboembolic events, which have limited or even 
contraindicated its use, as in the case of cerebral 
haemorrhage304,305. Exceptionally, the use of rFVIIa 
can be considered in patients with life-threatening 
haemorrhage and after the failure of conventional 
haemostatic treatments27. 
A good outcome and effective response to the use 
of rFVIIa do, however, require the prior restoration 
and control of some conditions: adequate levels of 
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platelets and plasma fibrinogen, almost physiological 
levels of pH and body temperature and correction of 
hypocalcaemia88,256. 
Off-label administration of rFVIIa (90 μg/kg) is 
suggested for the treatment of bleeding uncontrolled by 
conventional surgical or radiological treatment and/or in 
the case of failure of haemostatic therapy [2C].
Post-operative period
Autologous transfusion techniques 
Post-operative blood recovery
Post-operative blood recovery consists in collecting 
the blood that the patient loses through surgical drains 
into a specific container and subsequently re-infusing it 
into the patient306. This procedure can make use of two 
systems: "no wash" and "wash". 
With the "no wash system" the blood is transferred 
from the container connected to the drains to the infusion 
set and is re-infused without undergoing further treatment. 
There is an integrated double filtration system with a first 
filter of 100-200 μ, for fibrin and macroaggregates, and a 
second filter of 40 μ for microaggregates. Anticoagulants 
are not necessary because this blood does not contain 
fibrinogen. This system involves simple, economic and 
easy-to-use methods. 
The "wash system" involves the use of specific 
equipment which centrifuges the blood collected, 
eliminates the supernatant, washes the red blood cells and 
resuspends them in saline solution. This system is more 
demanding and staff require careful training in its use. 
The main controversies regarding the use of 
unwashed blood concern the volume of blood that can 
be recovered, which is often less than a therapeutic 
dose, the quality and safety of the blood, because of the 
numerous contaminants that it contains, and the lack 
of adoption of transfusion triggers to decide when to 
transfuse the patient307-310. 
However, although intuitively washing could reduce 
the presence of contaminants in recovered blood and 
the possible complications in recipients associated with 
their administration308, it should be remembered that, 
at present, there are no direct comparisons between 
blood products obtained with the two methods and the 
outcomes associated with their use309. For this reason, 
further studies are needed to evaluate the safety of post-
operative blood recovery techniques that do not include 
washing of the recovered blood311. 
Post-operative blood recovery, both with and without 
washing, has varied efficacy in reducing the amount 
of transfusion support with allogeneic red blood cells 
both in elective joint prosthesis surgery and in spinal 
surgery212,312-316. 
Numerous meta-analyses have demonstrated the 
efficacy of TXA, also when applied topically289, in 
limiting post-operative bleeding in patients undergoing 
major orthopaedic surgery269-277,289,290,317,318: TXA could, 
therefore, further reduce the role of post-operative blood 
recovery techniques.
Furthermore, a recent randomised controlled trial 
demonstrated, in patients undergoing elective lower limb 
arthroplasty with pre-operative Hb above 130 g/L, that 
not only were intra-operative and post-operative blood 
recovery unable to decrease transfusion requirements, 
but they actually increased costs205. 
It is recommended that post-operative blood 
recovery is used in elective major orthopaedic surgery 
(hip arthroplasty, knee arthroplasty, spinal surgery) 
only in the case in which it is expected that the post-
operative blood loss will be ≥10% of the patient's 
circulatory volume despite implementing multimodal 
strategies, including integrated use of other blood-
conserving techniques (pharmacological, surgical 
and anaesthesiological), also taking into account the 
characteristics of the individual patient (bleeding risk, 
multiple alloimmunisation) [1B].
It is suggested that the use of "washed" blood should 
be preferred (both in orthopaedic surgery and in other 
settings) [2B]306. 
When using systems that do not include washing, 
it is suggested that the concentration of free Hb is 
determined before re-infusing the unwashed blood, 
in order to check that the degree of haemolysis is less 
than 0.8% of the red cell mass contained in the product 
transfused into the patient [2C]306,319-321. 
Control of body temperature and prevention of stress 
ulcers
For the reasons already set out, patients must 
maintain a body temperature suitable for optimal 
haemostatic function also in the post-operative period. 
In this period a patient's body temperature may be low 
because of ineffective treatment of a possible intra-
operative hypothermia, because of the prolongation 
of thermomodulatory effects of anaesthetics or 
because of admission in poorly heated rooms322. It is, 
therefore, essential that the patient's body temperature 
continues to be monitored also in the period following 
any surgical procedure and that all methods and 
strategies useful for preventing hypothermia (blankets, 
warming fluids administered intravenously, etc.) are 
implemented.
It is recommended that the patient's body 
temperature is monitored also in the post-operative 
period, implementing all strategies aimed at preventing 
hypothermia [1C].
Classically, all patients subjected to a state of stress 
(including that related to a surgical intervention) are at 
risk of upper gastrointestinal tract bleeding. Decades 
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of research have demonstrated the advantages of 
pharmacological prophylaxis of this complication; such 
prophylaxis lowers the incidence of gastrointestinal 
bleeding deriving from the development of stress-
induced gastritis and is based on the use of various 
categories of drugs: proton pump inhibitors, antagonists 
of histamine H2 receptors and sucralfate. In critically 
ill patients, proton pump inhibitors seem to be 
more effective than the antagonists of histamine H2 
receptors in preventing clinically important bleeding 
from the upper gastrointestinal tract. The robustness 
of this conclusion is, however, limited by the poor 
methodological quality of the studies available, by 
differences between them and by possible publication 
bias323. Recent observational studies do, however, 
suggest that bleeding from stress ulcers is very rare. 
Furthermore, the risk of bleeding does not seem to be 
modified significantly by the use of acid-suppressing 
therapy which could even cause a potential increase in 
the risk of pneumonia and infections by Clostridium 
difficilis because of excessive alkalinisation of the 
gastric secretions324,325.
Because it is considered that the mechanism 
responsible for stress-induced gastritis is a decrease 
in blood flow in the mucosa, with consequent tissue 
ischaemia, it is thought that early recovery of central 
alimentation, which improves mucosal blood flow, can 
lower the risk of occult or clinically evident bleeding. 
However, the clinical studies that have evaluated the 
efficacy of this strategy compared with acid-suppressing 
drugs have yielded variable results and, so far, 
randomised controlled trials have not been performed326. 
It is suggested that prophylaxis of stress-induced 
gastrointestinal tract ulcers is not given. This suggestion 
does not apply to patients in the intensive care unit and 
those already with local disorders for which prophylaxis 
is specifically indicated [2C].
Careful monitoring of the patient and management of 
post-operative bleeding
Anticoagulant treatment and pharmacological 
interactions
In the post-operative period, re-introduction of 
anticoagulant therapy or the start of anticoagulant 
prophylaxis, dictated by the need to protect the 
patient from the risk of thromboembolism compels an 
evaluation of bleeding risk.
There are two main mechanisms by which 
anticoagulant drugs are metabolised and eliminated 
from the body: the cytochrome system (CYP450) and 
the P-glycoprotein transport system327. All the drugs or 
substances that activate or inhibit these systems can have 
repercussions on the anticoagulant effect which will be 
inhibited or potentiated. 
At present, few interactions between NOAC and food 
are known. Table IV327 reports the possible interactions 
between NOAC and other drugs; these interactions 
are based on the mechanisms of metabolism and it is 
important to know them because elderly patients are 
ever more frequently taking multiple drugs concurrently 
over the long term327. 
Many of the numerous interactions between warfarin 
and other drugs, or food, are due to the former's almost 
exclusive hepatic clearance, mediated by CYP450, in 
particular the isoform CYP2C9. In contrast, dabigatran 
seems to be metabolised in the plasma and liver without the 
intervention of CYP450, but is a substrate for P-glycoprotein 
and, for this reason, is susceptible to the effects of inhibitors 
or activators of P-glycoprotein. Rivaroxaban and apixaban 
are metabolised by the CYP3A4 isoform of CYP450 
and are also substrates for P-glycoprotein328, thus being 
sensitive to inhibitors and inducers of both systems. 
However, the demonstrated pharmacological interactions 
only make dose adjustments of NOAC necessary in 
some cases. Other possible interactions are caused by the 
association with non-steroidal anti-inflammatory drugs and 
platelet anti-aggregants329. 
Monitoring the patient and post-operative bleeding
In the post-operative period the patient may be 
subject to both thromboembolic and haemorrhagic 
complications.
In the post-operative period, it is recommended 
that antiplatelet therapy is restarted as early as possible, 
to prevent platelet activation and possible thrombotic 
complications [1C].
It is suggested that the first post-operative dose of 
clopidogrel or prasugrel is administered no more than 
24 hours after the end of the operation [2C]. 
It is suggested that this first post-operative dose is 
not a loading dose [2C].
Although the use of transfusion targets, determined 
by coagulation tests or POC tests, are used to guide 
treatment with blood components, these tests are not 
useful for monitoring thrombotic risk330-333. The evidence 
for post-operative use of platelet function tests (PFA-
200, MEA) is very limited334,335. 
Some studies have shown that desmopressin can 
improve altered platelet function in volunteers treated with 
aspirin or clopidogrel336,337; however, its use in acquired 
bleeding disorders is not supported by solid evidence. 
Despite the lack of studies on the capacity of 
transfused platelets to overcome the effect of treatment 
with clopidogrel or prasugrel, the management of 
important bleeding in patients being treated with 
antiplatelet drugs is based on the transfusion of 
platelets338. Likewise, studies have not been performed 
on the efficacy of platelet transfusions in patients being 
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treated with ticagrelor; the presence of this drug in the 
plasma makes the transfusion of platelets ineffective 
when the drug has been administered in the preceding 
12 hours88. 
It is suggested that platelets are transfused in the case 
of intra-operative or post-operative bleeding, clearly 
related to the intake of antiplatelet agents (aspirin, 
clopidogrel, prasugrel) [2C].
Unfractionated heparin (UFH) and LMWH are used in 
bridging therapy, in peri-operative thromboprophylaxis, 
in the treatment of venous thromboembolism, in 
disseminated intravascular coagulation and for 
anticoagulation in haemodialysis and heart surgery.
The aPTT and measurement of anti-FXa activity are 
able to determine the anticoagulant effect of UFH and 
LMWH, respectively, even if these tests are only useful 
in particular circumstances in the context of surgery.
The anticoagulant effect of heparins can be corrected 
rapidly by the intravenous administration of protamine 
sulphate (1 mg of protamine neutralises 100 IU of UFH 
or 100 units of anti-FXa of LMWH)339; however, the 
correction induced by protamine is less efficient in the 
case of subcutaneous administration of UFH or LMWH 
and it may, therefore, be necessary to prolong the 
intravenous infusion of protamine or give a second dose. 
It is recommended that bleeding associated with the 
intravenous administration of UFH is treated with an 
intravenous infusion of protamine sulphate at a dose of 
1 mg per 100 IU of UFH administered in the preceding 
2-3 hours [1A].
It is suggested that bleeding associated with 
subcutaneous administration of UFH that does not 
respond to intravenous protamine sulphate (1 mg per 
100 IU of UFH) is treated with a continuous intravenous 
infusion of protamine sulphate at a dose guided by the 
aPTT [2C].
It is suggested that bleeding associated with 
subcutaneous administration of LMWH is treated with 
intravenous protamine sulphate at a dose of 1 mg per 
100 units of anti-FXa of LMWH administered [2C].
If there is no response, it is suggested that a second 
dose of protamine sulphate is given (0.5 mg per 100 units 
of anti-FXa of LMWH administered) [2C].
Fondaparinux is a synthetic analogue of the 
polysaccharide sequence present in UFH and LMWH 
with a selective action on FXa, which is inactivated after 
binding to antithrombin. It is used in the prophylaxis and 
treatment of thromboembolic diseases and myocardial 
infarction. There is no antidote for fondaparinux; on 
the basis of in vitro studies, it has been proposed that 
rFVIIa is given to control severe bleeding caused by the 
administration of fondaparinux339,340.
It is suggested that bleeding related to the 
subcutaneous administration of fondaparinux is treated 
with rFVIIa (off-label use) [2C].
Pharmacological VKA, such as acenocoumarol 
(sintrom) and warfarin (coumadin) and others not 
yet available in Italy, are used for the prophylaxis 
or treatment of ischaemic and thrombotic events in 
patients with mechanical prosthetic heart values, in 
atrial fibrillation and in thromboembolic disease. With 
an increase in the number of elderly subjects and of 
disorders associated with thromboembolism, treatment 
with VKA is becoming ever more widespread and thus 
the bleeding complications of these drugs are becoming 
more frequent.
The anticoagulant effect of VKA can be rapidly 
reversed by the prompt use of PCC341-347, although there 
are no randomised controlled trials supporting their use 
in a setting other than haemophilia and the therapeutic 
dose has not been standardised because of the differences 
between the individual products256. 
The therapeutic anticoagulant effect of VKA is 
evaluated by measuring the INR which, before a surgical 
interventions, should be 1.5 or less. To achieve such a 
level, the Federation of Centres for the Diagnosis of 
Thrombosis and Monitoring of Antithrombotic Therapy 
argues for rapid neutralisation of VKA by intravenous 
administration of vitamin K and PCC, at a dose regulated 
on the basis of the pre-operative value of the INR348. 
Table IV - Interactions between new oral anticoagulants and other drugs (modified from Pengo V et al.327).
Dabigatran Rivaroxaban Apixaban
Glycoprotein-P inhibitors: amiodarone, phenothiazine, thioxanthenes, carboxylic acid, azole 
antifungal agents, verapamil, antimalarial drugs, cyclosporine
Yes Yes Yes
Glycoprotein-P inducers: dexamethasone, rifampicin, hypericum* Yes Yes Yes
Cytochrome CYP3A4 inhibitors: phenothiazine, carboxylic acid, azole antifungal agents, 
verapamil, erythromycin, telithromycin, nefazodone, antimalarial drugs, cyclosporine, 
thioxanthenes
No Yes Yes
Cytochrome CYP3A4 inducers: carbamazepine, efavirenz, nevirapine, phenytoin, phenobarbital, 
rifabutin, rifapentin, hypericum*, alcohol, eucalyptol
No Yes Yes
Non-steroidal anti-inflammatory drugs: aspirin, naproxen, diclofenac Yes Yes Yes
Anti-platelet drug: clopidogrel Yes Yes Yes
*: or St. John's wort, Hypericum perforatum.
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Since the use of PCC exposes treated patients to 
an increased risk of arterial and venous thrombosis, 
thromboprophylaxis should be resumed as soon as the 
bleeding has been controlled.
In patients receiving oral anticoagulant treatment 
with VKA who must undergo urgent surgery or who 
develop bleeding complications in the post-operative 
period, it is recommended that the anticoagulant 
therapy is interrupted immediately, that 10-20 mg of 
vitamin K1 is administered as soon as possible by slow 
intravenous infusion (15-30 minutes) and that PCC is 
infused slowly at the following doses: 20 IU/kg, if the 
INR is <2; 30 IU/kg, if the INR is between 2 and 3.9; 40 
IU/kg, if the INR is between 4 and 5.9; and 60 IU/kg, if 
the INR is >6 [1B].
In recent years, NOAC (dabigatran, rivaroxaban, 
apixaban) are becoming increasingly used for the prophylaxis 
and treatment of thromboembolic events. The current lack 
of valid laboratory tests able to measure their effective 
anticoagulant action makes therapeutic monitoring futile, 
whereas such monitoring is essential for VKA.
However, there is a specific test to measure the 
anti-FXa activity of the new anticoagulants with an 
anti-FXa effect (rivaroxaban, apixaban)349 and there 
is also a method to evaluate the inhibitory effect of 
the drugs with an anti-thrombin mechanism of action 
(dabigatran): the diluted thrombin time119. However, 
an accepted protocol for their peri-operative use has 
not yet been established.
No evidence-based recommendations can be 
made on the use of laboratory tests in the post-operative 
evaluation of the anticoagulant effect of NOAC. 
Whereas there is an antidote for VKA, there is not a 
specific antidote to neutralise the anticoagulant effect of 
NOAC, whether their mechanism of action is anti-FXa 
or anti-thrombin339.
Clinical experience is very limited and the 
paucity of published studies does not allow specific 
recommendations to be made. However, it has recently 
been demonstrated, in healthy volunteers, that the effect 
of these drugs on the tests of inhibition of FXa can be 
quickly and completely corrected by high doses of PCC 
(50 IU/kg); in contrast, this same dose does not correct 
the prolongation of the aPTT and thrombin time induced 
by dabigatran350. 
In the case of direct inhibitors of thrombin 
(dabigatran), the anticoagulant effect has been corrected 
by dialysis or the administration of activated concentrates 
of PCC (FEIBA), although the guidelines of the 
European Heart Rhythm Association suggest using PCC, 
as for other NOAC114. There is little evidence in favour 
of the use of rFVIIa114,351,352. 
In patients being treated or suspected of being 
treated with oral anti-FXa agents, such as rivaroxaban 
or apixaban, it is suggested that anti-FXa activity is 
determined, where this test is available [2C].
In the presence of important bleeding, it is 
suggested that the effect of rivaroxaban or apixaban 
is neutralised with high doses of PCC (25-50 IU/kg) 
or with activated PCC (50 U/kg, repeated if necessary) 
or rFVIIa (90 μg/kg) [2C].
In the presence of important bleeding in patients 
being treated with oral direct inhibitors of thrombin, such 
as dabigatran, it is suggested that high doses of PCC 
(25-50 IU/kg) are administered, or activated PCC (50 
U/kg, repeated if necessary) or rFVIIa (90 μg/kg) [2B].
The more common and less severe platelet disorders 
respond well to desmopressin, which shortens the 
bleeding time, whether used as prophylaxis or for the 
treatment of bleeding144-146. When used, the standard 
dose is 0.3 μg/kg, diluted in 50 mL of saline solution and 
infused slowly, over more than 30 minutes144. The use 
of antifibrinolytic drugs in inherited platelet disorders 
is not evidence-based.
In patients with inherited disorders of platelet 
function, it is suggested that desmopressin is used for 
the prevention and control of post-operative bleeding, 
and that TXA is used as an adjuvant [2C].
rFVIIa is indicated for the treatment of bleeding only 
in patients with Glanzmann's thrombasthenia, whereas 
it is not indicated for any other congenital or acquired 
platelet disorders. When used, the proposed dose is 
90 μg/kg, repeated every 2 hours for 12 hours and, 
subsequently, every 3-4 hours until the bleeding stops142. 
It is recommended that rFVIIa is used in the 
treatment of bleeding in patients with Glanzmann's 
thrombasthenia [1C].
Patients with thrombocytopenia resemble subjects 
with modest platelet disorders as far as concerns the 
treatment of post-operative bleeding complications153 
and should be treated on the basis of the platelet count 
and concomitant clinical conditions152-155,306,353,354. 
In patients with platelet disorders with a platelet 
count between 50 and 100×109/L, it is suggested that 
transfusion of platelet concentrates is considered if there 
is a high bleeding risk or a risk of bleeding in critical 
sites such as the eye or brain [2C]150,152,306. 
In the case of congenital functional platelet 
deficiencies, it is suggested that transfusion of platelet 
concentrates is considered, independently of the platelet 
count, in the presence of peri-operative bleeding not 
related to the surgery or to other clotting disorders 
[2C]150,152,306.
Among the bleeding disorders due to a congenital or 
acquired deficiency of clotting factors, the lack of VWF 
is undoubtedly the most widespread and the treatment, in 
the case of post-operative bleeding, is as recommended 
below13,131,133,136,137.
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It is recommended that the post-operative 
management of the patient with vWD is conducted 
in collaboration with an expert in haemostasis and 
thrombosis [1C].
In the presence of mild, post-operative bleeding 
in a patient with vWD, it is recommended that 
desmopressin is used, after a trial test, at doses 
described in specific guidelines (0.3 μg/kg, diluted in 
50 mL of saline solution and infused slowly, over more 
than 30 minutes) [1C]136-140.
In vWD patients with severe post-operative bleeding it 
is recommended that replacement therapy with plasma-
derived vWF or vWF-rich FVIII is given, according to 
the treatment regimens set out in specific guidelines [1C].
In vWD patients undergoing major surgery, it 
is suggested administering antifibrinolytics in the 
post-operative period, as an adjuvant to more specific 
treatment, and platelet transfusions, only in the case of 
failure of other treatments [2C].
It is recommended that the post-operative 
management of patients with haemophilia or other 
congenital bleeding disorders is conducted in 
collaboration with an expert in haemostasis and 
thrombosis [1C].
Personalised thromboprophylaxis is suggested 
in the post-operative period in haemophilic patients 
undergoing major surgery [2C]163.
For patients with deficiencies of FVIII (haemophilia 
A) or FIX (haemophilia B) without inhibitors, the 
recommendations for post-operative management are 
reported below140,156,158,160.
It is recommended that appropriate replacement 
therapy is given [1C].
It is suggested that published guidelines are followed 
when giving replacement therapy (target of the missing 
factor and duration of treatment) [2C].
For replacement treatment in the post-operative 
period, it is recommended that either recombinant or 
plasma-derived concentrates are used [1C].
The suggested treatment in patients with inhibitors 
is rFVIIa or activated PCC (FEIBA) [2C].
rFVIIa is the treatment of choice for congenital 
deficiency of FVII; if this is not available, plasma 
concentrate of FVII is preferred over PCC, because of 
the potential prothrombotic effect of these latter140,164.
In the post-operative period in patients with 
congenital deficiency of FVII, it is suggested that 
plasma concentrate of FVII, at a dose of 10-40 IU/kg, 
is used as an alternative to rFVIIa [2C]164.
In the post-operative period in patients with 
congenital deficiency of FVII undergoing major surgery, 
it is suggested that rFVIIa, at a dose of 15-30 μg/kg 
every 4-6 hours, is used, usually for a minimum of three 
doses [2B]164. 
In cases of congenital deficiency of fibrinogen 
and FXIII, the British guidelines recommend the use 
of specific concentrates164. In hypofibrinogenaemia, 
replacement therapy is indicated for fibrinogen levels 
<1 g/L or <20-30% of normal. However, a possible 
risk of thrombosis must be kept in mind when plasma 
fibrinogen concentrates are used.
In the case of a congenital lack of FV and FXI, 
fresh-frozen plasma, preferably a industry-produced, 
virus-inactivated product, is the only therapeutic 
option, also in the post-operative period164. Patients 
with FXI deficiency and inhibitors undergoing surgery 
can be treated successfully with low doses of rFVIIa 
(33-47 μg/kg)168; the contemporary administration 
of TXA was found to be effective in controlling 
bleeding164.
PCC are the reference concentrates for the treatment of 
FII and FX deficiencies, for which specific concentrates 
are not available164,169,170. 
In patients with other rare clotting factor 
deficiencies no evidence-based recommendations 
can be made on the peri-operative use of rFVIIa, 
desmopressin or TXA. 
Management  o f  the  pa t ien t  wi th  acqui red 
thrombocytopenia
It is suggested that the decision to transfuse platelet 
concentrates in the post-operative period is not based 
exclusively on a low platelet count, but also on the 
clinical conditions of the patient (in particular, body 
temperature >38.5 °C, plasma clotting disorders, recent 
bleeding, neurological deficits) [2C]150,152,306. 
Platelet transfusion is rarely indicated in the 
surgical patient with normal platelet function in whom 
the platelet count is greater than 100×109/L; such a 
transfusion is suggested, however, when the count 
is less than 50×109/L and there is excessive bleeding 
[2C]150,152,306. 
In the case of intermediate values (platelet count 
between 50×109/L and 100×109/L) it is suggested that 
platelet transfusions are considered in specific situations 
such as secondary platelet dysfunction or when there is 
a risk of bleeding in critical sites, such as the eye and 
brain [2C]150,152,306. 
In the case of an acquired deficit of platelet function 
(for example: anti-aggregant drugs, cardiopulmonary 
by-pass) it is suggested that platelet transfusions are 
administered, independently of the platelet count, in 
the presence of peri-operative bleeding not related to 
the surgery or to other clotting disorders [2C]150,152,306. 
In the case of acute disseminated intravascular 
coagulation, in the presence of major bleeding and 
thrombocytopenia, it is suggested that the platelet count 
is maintained around 50×109/L [2C]306. 
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In patients with disseminated intravascular 
coagulation who are not bleeding, prophylactic 
transfusion of platelet concentrates is suggested in 
cases in which the thrombocytopenia and stratification 
of bleeding risk indicate a high probability of bleeding 
[2C]306. 
It is suggested that prophylactic platelet transfusion 
is not used routinely when the thrombocytopenia is 
due to increased platelet destruction (heparin-induced 
thrombocytopenia, autoimmune thrombocytopenia, 
thrombotic thrombocytopenic purpura) because it is 
ineffective in these cases [2C]152,306. 
In anaemic, thrombocytopenic patients (platelet 
count ≤20×109/L) without active bleeding, it is 
suggested that the haematocrit is increased to about 
30% to reduce the bleeding risk [2B]306. 
Optimising tolerance of anaemia
Pre-operative period
Evaluation and optimisation of the individual 
physiological reserve for tolerance of anaemia and 
risk factors 
Since the decrease in availability of oxygen in an 
acute episode of anaemia is initially compensated for by 
an increase in cardiac output, the compensatory cardiac 
reserve could be used to determine the tolerance to 
anaemia. However, although evaluating cardio-respiratory 
functional reserve in patients who are candidates for 
surgery is part of daily clinical practice for anaesthetists, 
estimating tolerance of anaemia in an individual patient 
remains a challenge that has not been completely won. 
In fact, there are not yet methods or investigations that 
enable the tolerance of anaemia of a given patient to be 
predicted a priori355. There are, however, various, detailed 
guidelines to which the reader is referred356-359. 
In any case, it is worth remembering some key 
concepts here: 
- pre-operative evaluation of the cardiac reserve is 
performed primarily to identify those patients for 
whom cardiac stress related to the operation and to 
the peri-operative period could represent a particular 
risk for morbidity or mortality which would be 
associated with the risk already present due to the 
patient's underlying condition. From this point of 
view, the tolerance of anaemia is deduced from the 
real state of compensation and the cardiac reserve, 
determined by various tests355. 
- There is little evidence from well-conducted, 
randomised trials and many recommendations are 
based mainly on experts' opinions359. 
- In the last 5-10 years, various steps forward have 
been made. Greater emphasis is now given to 
stratification of clinical risk rather than to routine 
cardiac testing360. 
- The same considerations apply to the pre-operative 
evaluation of respiratory function and, given the 
increase in the current day population of overweight 
subjects, also to the metabolic evaluation361. 
In all patients potentially at risk of acute peri-
operative anaemia, it is recommended that the cardio-
respiratory reserve is evaluated during the pre-operative 
assessment, using specific diagnostic protocols and 
flow-charts based on the best, periodically updated 
indications [1C]. 
Adoption of restrictive transfusion thresholds
Most of the currently available guidelines recommend 
basing decisions on transfusion therapy with red 
blood cells on both the patient's Hb values as well as 
symptoms of anaemia (chest pain, congestive heart 
failure, tachycardia not responsive to the administration 
of fluid or postural hypotension)12,199,306,362-366. Although 
the search for physiological transfusion triggers that are 
most indicative of the state of tissue oxygenation and 
the presence of ischaemia continues to be a subject of 
research, at present there are no data from clinical studies 
that support the use of such measurements, which have, 
in any case, not yet been validated in clinical practice367. 
The Hb concentration does, therefore, remain the most 
widely used transfusion trigger, together with clinical 
assessment of the patient.
Following the Transfusion Requirements in Critical 
Care (TRICC) clinical trial368, published in 1999, various 
studies showed that adopting a restrictive transfusion 
threshold (Hb=70-80 g/L) guarantees patients' safety 
while reducing transfusion use.
In particular, in orthopaedic patients, the recent 
transfusion trigger trial for Functional Outcomes in 
Cardiovascular patients Undergoing Surgical hip fracture 
repair (FOCUS) demonstrated, in elderly patients at high 
cardiovascular risk, that a liberal strategy (Hb transfusion 
threshold=100 g/L) did not reduce mortality, the rate of 
inability to walk autonomously at 60 days after surgery 
or even morbidity during the admission, in comparison 
with a restrictive strategy (Hb transfusion threshold 
>80 g/L or symptomatic anaemia)369. These results were 
recently further supported by a post-hoc analysis of a 
randomised study of patients undergoing lower limb 
prosthetic surgery370 and by a meta-analysis371. 
The greater efficacy of a restrictive transfusion 
threshold (Hb<70 g/L) compared to the liberal one 
(Hb<90 g/L) was also supported by a significantly 
lower mortality in patients with gastrointestinal 
bleeding372. 
Another randomised study demonstrated that a 
restrictive strategy (haematocrit >24%) and a liberal 
one (haematocrit >30%) were equally safe in patients 
undergoing heart surgery373. 
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On the other hand, a recent pilot study in patients 
with acute coronary syndrome showed that the liberal 
transfusion strategy was associated with a better 
outcome in this particular setting374. 
It is recommended that a restrictive transfusion 
threshold (Hb 70-80 g/L) is adopted in all hospitalised, 
clinically stable patients [1A].
It is suggested that a restrictive transfusion threshold 
is adopted in hospitalised patients with previous 
cardiovascular disorders [2B]. 
It is suggested that transfusion therapy is considered 
in hospitalised patients with previous cardiovascular 
disease if they are symptomatic or have a Hb≤80 g/L [2B].
It is suggested that hospitalised patients with 
acute coronary syndrome who are haemodynamically 
stable undergo a careful clinical evaluation, aimed at 
determining a personalised transfusion threshold [2C]. 
Intra-operative period 
Optimising cardiac output. Optimising ventilation and 
oxygenation
The availability of oxygen in the tissues is the 
product of the cardiac output and the arterial oxygen 
content. For this reason, from a physiological point 
of view, the availability of oxygen in tissues can be 
stabilised by manipulating the two factors involved.
There is currently more and better clinical evidence 
regarding optimisation of haemodynamic function (or 
goal-directed therapy [GDT])375,376. However, two recent, 
randomised studies in surgical patients at high risk did 
not show a significant impact of GDT on outcome377,378. 
The physiological rationale underlying GDT is that 
bringing a patient's cardiovascular function to an 
optimal level, through a specific, codified therapeutic 
approach, ensures the best oxygen supply to tissues 
in that individual patient. GDT is, therefore, mainly 
based on the intravenous administration of fluids, but 
also cardio-active drugs, in doses such as to bring the 
individual patient to the part most efficient of his or her 
cardiac performance, as expressed by the Maestrini-
Starling law379,380. This objective can only be achieved 
if systems for haemodynamic monitoring are used 
that evaluate cardiac output rather than the so-called 
"filling pressure", heart rate or mean systemic blood 
pressure. In fact, these last parameters have now been 
considered for some years as insensitive indicators of 
hypovolaemia or changes in cardiac output381. Cardiac 
output has traditionally been evaluated by an invasively 
introduced Swan-Ganz catheter. More recently, less 
invasive, reliable monitoring instruments have become 
available (particularly in circumstances of totally 
assisted pulmonary ventilation)382-384. 
It has been amply demonstrated that the management 
of circulatory volume according to the principles 
of GDT also enables better dosing of fluid therapy, 
avoiding the complications related to the administration 
of too much or too little fluids, thus positively affecting 
the patients' outcome375,385-388. 
P rompt  i n t r a -ope ra t ive  managemen t  o f 
haemodynamics, according to the principles of GDT, 
is recommended [1B].
It is recommended that hypervolaemia and 
hypovolaemia are avoided [1B].
It is recommended privileging systems that monitor 
blood flow in order to guide fluid therapy [1B].
In cases in which the patient is undergoing 
mechanical ventilation, the intra-operative availability 
of oxygen in the tissues could also be improved by 
increasing the inspired fraction of oxygen (FiO2), 
since this is able to increase the arterial partial 
pressure of oxygen proportionally. Furthermore, 
because of the great difference in the partial pressure 
of oxygen between blood and tissues, in conditions of 
marked anaemia, an increase in the amount of oxygen 
physically dissolved in the blood, which is obtained by 
ventilation with high FiO2, can improve tissue oxygen 
availability. In this regard, it has been demonstrated 
in animal models that hyperoxic ventilation increases 
the rate of survival and tolerance of anaemia by 
guaranteeing tissue oxygenation even at very low 
levels of Hb389-392. Thus, hyperoxic ventilation can be 
considered for patients with acute anaemia undergoing 
general anaesthesia. However, at present there is a 
lack of large clinical studies demonstrating that this 
method does actually improve tissue oxygenation 
during acute, severe anaemia. Furthermore, there 
are not yet controlled studies clarifying whether 
ventilation with high concentrations of oxygen can 
really improve survival in cases of acute anaemia that 
continues for prolonged periods. Finally, it should 
be remembered that the side effects of prolonged 
hyperoxic ventilation (arteriolar vasoconstriction, 
generation of oxygen radicals and formation of 
atelectasis) can outweigh the positive effects on 
oxygen transport and tissue oxygenation355. However, 
considering that the exposure is limited in time (intra-
operative period) it is reasonable to expect that the 
damage known to occur with prolonged hyperoxia 
does not develop in surgical patients treated with 
this method393. 
In the case of acute intra-operative anaemia in 
patients undergoing general anaesthesia and mechanical 
ventilation, it is suggested that hyperoxic pulmonary 
ventilation is administered (FiO2=1). This technique, 
especially if used in combination with normovolaemic 
haemodilution, can be useful, at least to enable greater 
availability of tissue oxygen until the bleeding is 
controlled [2C].
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Post-operative period
Optimising the tolerance of anaemia. Maximising 
oxygen delivery. Minimising oxygen consumption
The considerations on maximising oxygenation in 
the intra-operative period are essentially valid also in the 
post-operative period. However, it is worth emphasising 
that the techniques used necessitate monitoring and 
a level of knowledge and specific skills that strongly 
suggest that the post-operative management of patients 
at risk is performed in appropriately equipped healthcare 
settings (recovery room, intensive care unit, sub-
intensive care unit)394,395. 
Indeed, one aspect worth highlighting is that post-
operative complications, including those due to poor 
tolerance of anaemia, if not promptly identified and 
treated adequately, can have a substantial impact on 
both the patient and the whole healthcare system, since 
they can be potentially disastrous for the former and 
associated with prolonged admissions, with increased 
costs, for the latter. In this regard, recent data suggest 
that these costs could be due not only to the short-term 
management of the patient, but also to the long-term 
management, because of repeated hospital admissions 
for recurrences and the development of a state of chronic 
disease396-398. 
In the case of patients with a reduced physiological 
reserve, which may cause a peri-operative reduction 
in tolerance of anaemia, it is recommended that post-
operative observation is planned for an appropriate 
period (the duration of which varies according to the 
attendant clinician) in settings of variable intensity 
of care depending on the patients' requirements. In 
these structures it should be possible to monitor and, if 
necessary, support the physiological variables involved 
in the process of adaptation to anaemia [1C].
It has been known for many years that there is a 
relationship between post-operative pain, stress and 
oxygen consumption399. Furthermore, acute post-
operative pain, if not adequately treated, causes a series 
of reflexes that alter physiological homeostasis, such 
as the secretion of catabolic hormones, with significant 
haemodynamic, renal and immune repercussions. 
Finally, post-operative pain causes important 
respiratory alterations, inducing a restrictive syndrome. 
In particular the activity of the diaphragm and other 
respiratory muscles is reduced after abdominal surgery. 
The logical consequences of this are a change in the 
ventilation/perfusion ratio and a greater probability 
of developing hypercapnia, hypoxia, atelectasis and 
inflammatory lung phenomena400,401. Consequently, 
pain is nowadays considered a complication of surgery, 
rather than a simple symptom, and does, therefore, 
require appropriate treatment according to well-defined 
protocols402,403. 
Epidural analgesia is a consolidated technique that, 
for several years, has been considered the gold standard 
in the management of post-operative pain, particularly 
in the elderly and in patients with impaired respiratory 
function404-407. However, recent data show that the 
benefits of this technique are not as great as thought 
and that the advantages with regard to decreasing 
the incidence of cardiovascular and respiratory 
complications are probably limited to high-risk patients 
undergoing abdominal or thoracic surgery who receive 
thoracic epidural analgesia only with local anaesthetics. 
Furthermore, there is recent evidence showing that less 
invasive, regional analgesic techniques (paravertebral 
block for thoracotomy, femoral block for hip and knee 
surgery, local infiltrations - possibly continuous - of the 
wound, local analgesic infiltration in lower limb surgery) 
are as effective as epidural analgesia. For this reason, the 
number of indications for epidural analgesia seems to be 
decreasing408-413. In orthopaedic limb surgery, the use of 
continuous peripheral nerve blocks has been shown to 
be as effective as peridural analgesia414-417. 
In order to optimise the treatment of pain, it is 
recommended that the level of post-operative pain 
(at rest and not) is evaluated periodically, using an 
international scales: a numerical rating scale, a visual 
analogue scale or a verbal rating scale. This information 
must be recorded in the patient's clinical records [1A].
Given their greater efficacy, it is recommended that 
epidural techniques of analgesia are used rather than 
systemic opioids [1A].
In limb surgery, it is recommended that continuous 
peripheral nerve blocks are used [1A].
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